Page last updated: 2024-11-06

sparfloxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Sparfloxacin is a synthetic fluoroquinolone antibiotic that was first synthesized in the 1980s. It is a broad-spectrum antibacterial agent effective against a wide range of gram-positive and gram-negative bacteria. Sparfloxacin is known for its high oral bioavailability and its ability to penetrate tissues, making it effective in treating respiratory tract infections, urinary tract infections, and skin infections. It inhibits bacterial DNA gyrase and topoisomerase IV, essential enzymes involved in DNA replication and repair. Sparfloxacin was initially studied for its potential benefits in treating bacterial infections, particularly those resistant to other antibiotics. However, its use has been limited due to concerns about its potential side effects, including hepatotoxicity, phototoxicity, and prolongation of the QT interval, which can increase the risk of cardiac arrhythmias. Despite its limitations, sparfloxacin remains a valuable tool for treating certain bacterial infections, particularly in situations where other antibiotics are ineffective or poorly tolerated.'

Cross-References

ID SourceID
PubMed CID60464
CHEMBL ID850
CHEBI ID9212
SCHEMBL ID41311
MeSH IDM0170192

Synonyms (126)

Synonym
AB00639950-02
5-amino-1-cyclopropyl-7-[(3r,5s)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-quinoline-3-carboxylic acid
at-4140
rp-64206
pd-131501
drg-0143
esparfloxacino [inn-spanish]
3-quinolinecarboxylic acid, 5-amino-1-cyclopropyl-7-((3r,5s)-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-, rel-
cp-103826
3-quinolinecarboxylic acid, 1,4-dihydro-5-amino-1-cyclopropyl-6,8-difluoro-7-(3,5-dimethyl-1-piperazinyl)-4-oxo-, cis-
3-quinolinecarboxylic acid, 5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-, cis-
cp 103826
brn 3658018
sparfloxacinum [inn-latin]
sparfloxacine [inn-french]
5-amino-1-cyclopropyl-7-[(3r,5s)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
CHEBI:9212 ,
sparfloxacin & ru 40555
5-amino-1-cyclopropyl-7-[(3s,5r)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-quinoline-3-carboxylic acid
at 4140
pd131501 ,
pd 131501
5-amino-1-cyclopropyl-7-(cis-3,5-dimethyl)-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid & ru 40555
spfx
ci 978
ci-978
5-amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
zagam
spara
cis-5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
C07662
sparfloxacin
110871-86-8
smr000466312
MLS000759417
NCGC00166294-01
NCGC00159333-02
DB01208
sparfloxacin (jan/usan/inn)
D00590
zagam (tn)
3-quinolinecarboxylic acid, 5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-
5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
sparfloxacin, >=98.0% (hplc)
AC-11574
HMS2090N19
CHEMBL850
nsc-759641
5-amino-1-cyclopropyl-7-[(3r,5s)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid
STK802067
A802376
AKOS005622503
NCGC00166294-02
dtxsid9023590 ,
dtxcid50820154
tox21_111580
cas-110871-86-8
BBL010957
sparfloxacine
sparfloxacinum
esparfloxacino
nsc 759641
unii-q90aga787l
parox
sparfloxacin [usan:inn:ban:jan]
q90aga787l ,
pd 1315-1
bdbm50366822
EPITOPE ID:119065
S1884
sparfloxacin [mart.]
sparfloxacin [jan]
sparfloxacin [usan]
sparfloxacin [vandf]
sparfloxacin [inn]
sparfloxacin [who-dd]
sparfloxacin [mi]
sparfloxacin [orange book]
CCG-221166
HY-B0308
S0896
5-amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid
S-6990
SCHEMBL41311
NCGC00166294-03
tox21_111580_1
KS-5009
sparfloxacin, antibiotic for culture media use only
5-amino-1-cyclopropyl-6,8-difluoro-7-(cis-3,5-dimethyl-1-piperazinyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid
DZZWHBIBMUVIIW-DTORHVGOSA-N
AB00639950_03
mfcd00869619
sr-01000759357
SR-01000759357-2
5-amino-1-cyclopropyl-7-((3r,5s)-3,5-dimethylpiperazin-1-yl)-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
sparfloxacin, vetranal(tm), analytical standard
SR-05000001521-2
SR-05000001521-1
sr-05000001521
HMS3715J13
5-amino-1-cyclopropyl-7-((3s,5r)-3,5-dimethylpiperazin-1-yl)-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
rkl10082
SW199632-2
3-quinolinecarboxylic acid, 5-amino-1-cyclopropyl-7-[(3r,5s)-3,5-dimethyl-1-piperazinyl]-6,8-difluoro-1,4-dihydro-4-oxo-, rel-
at-4140 pound>>ci-978 pound>>ci 978 pound>>ci978 pound>>at 4140 pound>>at4140 pound>>pd 131501 pound>>pd131501 pound>>pd-131501
BCP23886
sparfloxacinhydrochloride
sparfloxacin,(s)
Q976559
5-amino-1-cyclopropyl-7-[(3s,5r)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid
BRD-K07612980-001-07-9
gtpl10860
ci978
at4140
4-bromo-1-(tert-butyl)-3-methyl-1h-pyrazole-5-carboxylicacid
A894831
5-amino-1-cyclopropyl-7-[(3s,5r)-3,5-dimethylpiperazin-4-ium-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylate
j01ma09
sparfloxacinum (inn-latin)
5-amino-1-cyclopropyl-7-((3r,5s)3,5-dimethylpiperazin-1-yl)-6,8-difluoro-4-oxo-quinoline-3-carboxylic acid
sparfloxacine (inn-french)
sparfloxacin (mart.)
5-amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid
esparfloxacino (inn-spanish)
Z1590783391
5-amino-1-cyclopropyl-7-[(3s,5r)-3,5-dimethyl-1-piperazinyl]-6,8-difluoro-4-oxo-3-quinolinecarboxylic acid

Research Excerpts

Overview

Sparfloxacin (SPFX) is a broad spectrum antibiotic which inhibits bacterial DNA gyrase enzyme activity. It is an antibiotic in the quinolone group of antibacterial agents, which often induce photosensitive skin reactions.

ExcerptReferenceRelevance
"Sparfloxacin is a quinolone carboxylic acid derivative that shows activity as an antimicrobial agent, against a wide range of Gram-negative and Gram-positive organisms. "( Simultaneous interaction, degradation, and kinetic study of sparfloxacin with H2 receptor antagonist.
Amir Hassan, -; Fouzia Shafi, -; Iffat Sultana, -; Maria Qureshi, -; Nazia Tabassum, -; Qurat Ul Aen Ismail, -; Sadia Iqbal, -; Shereen, -; Sohail Hassan, -; Tahreem Mujtaba, -, 2023
)
2.6
"Sparfloxacin (SPFX) is a broad spectrum antibiotic which inhibits bacterial DNA gyrase enzyme activity. "( PLGA nanoformulation of sparfloxacin enhanced antibacterial activity with photoprotective potential under ambient UV-R exposure.
Amar, SK; Chopra, D; Dubey, D; Dwivedi, A; Haldar, C; Kumari, S; Ray, L; Ray, RS; Singh, J; Srivastva, AK; Yadav, RK, 2018
)
2.23
"Sparfloxacin is an antibiotic in the quinolone group of antibacterial agents, which often induce photosensitive skin reactions, more often phototoxic reactions than photoallergic ones, and sometimes associated photo-onycholysis. "( Sparfloxacin-induced photo-onycholysis and photosensitivity characteristically sparing lepromatous skin lesions: an interesting observation.
Pawar, M; Singh, M, 2018
)
3.37
"Sparfloxacin is a broad-spectrum fluoroquinolone antibiotic commonly used for various bacterial corneal infections. "( Sparfloxacin-associated corneal epithelial toxicity.
Agarwal, AK; Ram, J; Singh, R, 2014
)
3.29
"Sparfloxacin seems to be a better antibiotic for topical application for themanagement of external ocular Infections like conjunctivitis, keratitis and corneal ulcers."( Evaluation of sparfloxacin eye drop in the management of conjunctival and corneal infection.
Desai, T; Shah, C; Vyas, U, 2002
)
1.4
"Sparfloxacin is a new fluoroquinolone with potent antitubercular activity. "( Torsade de pointes probably induced by sparfloxacin.
Byotra, SP; Kakar, A, 2002
)
2.03
"Sparfloxacin is a broad-spectrum oral fluoroquinolone antimicrobial agent with a long elimination half-life, extensively used against both Gram-positive as well as Gram-negative microorganism. "( Interactions between sparfloxacin and antacids - dissolution and adsorption studies.
Arayne, MS; Hussain, F; Sultana, N, 2006
)
2.1
"Sparfloxacin is a widely prescribed drug for various infections. "( Effects of sparfloxacin on CNS functions and urinary hydroxyproline in mice.
Bharal, N; Pillai, KK; Vohora, D, 2006
)
2.17
"Sparfloxacin seems to be a good candidate for antimycobacterial treatment. "( [A trial of clinical application of sparfloxacin for treating mycobacterial infections].
Aoki, N; Arakawa, M; Usuda, Y; Wada, K; Yoshikawa, H, 1995
)
2.01
"Sparfloxacin is a recently developed fluoroquinolone. "( Clinical pharmacokinetics of sparfloxacin.
Ishibashi, Y; Nogita, T; Shimada, J, 1993
)
2.02
"Sparfloxacin is a new antimicrobial that, while maintaining a good activity against gram negative bacilli, has a better in vitro activity against gram positive bacteria such as S pneumoniae, intracellular pathogens and anaerobic bacteria. "( [In vitro comparative activity (E test) of sparfloxacin and other 8 antimicrobial agents against bacteria isolated from patients with respiratory infections acquired in the community].
Braun, S; Juliet, C; Nina, A; Prado, V; Salamanca, L; Trucco, O, 1995
)
2
"Sparfloxacin is a fluoroquinolone active against both penicillin-susceptible and -resistant strains of Streptococcus pneumoniae."( In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens.
Baquero, F; Cantón, R, 1996
)
1.33
"Sparfloxacin is a piperazinyl, cyclopropyl-fluoroquinolone with broad-spectrum antibacterial activity. "( Sparfloxacin worldwide in vitro literature: isolate data available through 1994.
Cohen, MA; Talbot, GH; Yoder, SL, 1996
)
3.18
"Sparfloxacin is a fluoroquinolone antibacterial agent with activity against a broad range of Gram-negative and Gram-positive organisms including Streptococcus pneumoniae, one of the main pathogens in community-acquired pneumonia. "( Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.
Bryson, HM; Goa, KL; Markham, A, 1997
)
3.18
"Sparfloxacin (RP 64206) is a broad-spectrum fluoroquinolone with excellent activity in vitro against the majority of bacteria involved in community-acquired pneumonia, including pneumococcus."( Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study.
Brandon, ML; Donowitz, GR; Harman, CP; Salisbury, JP; Talbot, GH; Tipping, DM; Urick, AE,
)
2.3
"Sparfloxacin is a new oral fluoroquinolone antimicrobial that is highly active against common respiratory pathogens, including multiresistant strains. "( Sparfloxacin: potential clinical and economic impact in the treatment of respiratory infections.
Havlichek, DH; Stein, GE,
)
3.02
"Sparfloxacin is a fluoroquinolone with improved antibacterial activity against gram-positive pathogens. "( Chondrotoxicity and toxicokinetics of sparfloxacin in juvenile rats.
Borner, K; Förster, C; Merker, HJ; Schwabe, R; Shakibaei, M; Stahlmann, R; Zippel, U, 1998
)
2.01
"Sparfloxacin is a broad-spectrum oral fluoroquinolone antimicrobial agent with a long elimination half-life (t(1/2)). "( Effect of Maalox on the oral absorption of sparfloxacin.
Caille, G; Dorr, MB; Johnson, RD; Talbot, GH,
)
1.84
"Sparfloxacin is a suitable therapeutic alternative for the empiric treatment of respiratory tract infections owing to its favorable pharmacokinetic profile and activity against typical and atypical respiratory tract pathogens, even in geographic areas with a high incidence of penicillin resistance."( Comparison of the in vitro activity of and pathogen responses to sparfloxacin with those of other agents in the treatment of respiratory tract, urinary tract, and skin and skin-structure infections.
Acusta, A; Dorr, MB; Dowzicky, M; Nadler, H; Talbot, GH, 1999
)
1.26
"Sparfloxacin is a fluoroquinolone antimicrobial agent with a broad spectrum of activity and long elimination half-life. "( Pharmacokinetics of sparfloxacin in patients with renal impairment.
Dorr, MB; Jensen, B; Johnson, RD; Magner, D; Marbury, T; Talbot, GH, 1999
)
2.07
"Sparfloxacin is a highly effective and safe broad-spectrum antibacterial agent for the treatment of bacterial infections. "( [A randomized controlled clinical study of sparfloxacin versus ofloxacin in the treatment of bacterial infections].
Hu, D; Hu, P; Jiang, S; Jiang, Y; Li, S; Wang, Q; Zhu, L; Zou, Q, 1999
)
2.01
"Sparfloxacin is a new oral fluoroquinolone agent with putative activity against common pediatric pathogens. "( In vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients.
Akaniro, JC; Arguedas, AG; Stutman, HR; Vargas, OM, 1992
)
2.05
"Sparfloxacin (SPFX) is a new quinolone compound with a long half-life of 16 hours and a potent antibacterial activity (MIC90: < or = 0.025 micrograms/ml against Escherichia coli), suggesting that the agent can be effectively used in single-dose therapy for acute uncomplicated cystitis in female patients. "( [Dose finding study of sparfloxacin in single-dose therapy for female acute uncomplicated cystitis].
Hirose, T; Miyake, M; Miyamoto, S; Miyao, N; Sato, T; Takatsuka, K; Tanaka, N; Umehara, T; Yokoo, A; Yoshiaki, K, 1992
)
2.04

Effects

Sparfloxacin has good antimicrobial activity against several acid-fast bacteria. It is expected to be an effective drug for treating mycobacteriosis.

ExcerptReferenceRelevance
"Sparfloxacin has good antimicrobial activity against several acid-fast bacteria and is expected to be an effective drug for treating mycobacteriosis."( Antibacterial activity and clinical efficacy of sparfloxacin in Mycobacterium avium-intracellulare complex infection.
Handa, M; Horiguchi, T; Kondo, R; Miyazaki, J; Munekata, E; Shiga, M; Sugiyama, M,
)
1.11
"Sparfloxacin has greater anaerobic activity than levofloxacin, which is more active than ciprofloxacin or ofloxacin."( Levofloxacin and sparfloxacin: new quinolone antibiotics.
Chuck, SK; Jung, R; Martin, SJ; Messick, CR; Meyer, JM; Pendland, SL, 1998
)
1.36

Actions

ExcerptReferenceRelevance
"The sparfloxacin group had a lower frequency of digestive and nervous system adverse events, but a higher frequency of photosensitivity reactions than the ofloxacin group."( Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group.
Bensch, G; Chodosh, S; DeAbate, CA; Harper, L; Henry, D; Jubran, A; Talbot, GH; Tipping, D, 1998
)
2.22

Treatment

ExcerptReferenceRelevance
"All sparfloxacin-treated eyes remained culture negative."( Systemic prophylaxis of experimental staphylococcal endophthalmitis: comparative efficacy of sparfloxacin, pefloxacin, imipenem, vancomycin, and amikacin.
Carbon, C; Cochereau, I; Marrakchi-Benjaafar, S; Pocidalo, JJ, 1995
)
0.99

Toxicity

Domestic sparfloxacin is effective and safe in treating acute bacterial infections. Few serious adverse cardiovascular events have been reported. All have occurred in patients with an underlying cardiac condition.

ExcerptReferenceRelevance
"05%) was uniformly toxic to both cultured human cells and microorganisms; (2) nitrofurazone (0."( Cytotoxicity testing of topical antimicrobial agents on human keratinocytes and fibroblasts for cultured skin grafts.
Boyce, ST; Holder, IA; Warden, GD,
)
0.13
" The incidence of adverse events, the incidence and severity of antibacterial-related adverse events and the incidence of antibacterial discontinuation due to adverse events were no different among patients treated with sparfloxacin compared with those who received a comparator antibacterial agent."( Safety profile of sparfloxacin in the treatment of respiratory tract infections.
Rubinstein, E, 1996
)
0.81
" Few serious adverse cardiovascular events have been reported during post-marketing surveillance of sparfloxacin and all have occurred in patients with an underlying cardiac condition."( Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group.
Brumpt, I; Jaillon, P; Morganroth, J; Talbot, G, 1996
)
0.75
"1%) of 1331 receiving a comparator regimen experienced at least 1 adverse event considered to be related to the study medication."( Safety profile of sparfloxacin, a new fluoroquinolone antibiotic.
Dorr, MB; Lipsky, BA; Magner, DJ; Talbot, GH, 1999
)
0.64
"This paper focuses on the development of four major adverse drug reactions (ADRs) associated with some fluoroquinolones: convulsions, phototoxicity, cardiac effects, and hepatotoxicity."( Latest industry information on the safety profile of levofloxacin in Japan.
Yagawa, K, 2001
)
0.31
" The adverse reactions in the two groups were 13."( [Multicenter evaluation on the efficacy and safety of sparfloxacin in the treatment of acute bacterial infections].
Cai, Y; Liang, D; Miao, J; Qiu, D; Wen, C; Xu, N, 2002
)
0.56
"Domestic sparfloxacin is effective and safe in treating acute bacterial infections."( [Multicenter evaluation on the efficacy and safety of sparfloxacin in the treatment of acute bacterial infections].
Cai, Y; Liang, D; Miao, J; Qiu, D; Wen, C; Xu, N, 2002
)
0.98
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Topical use of fluoroquinolones is considered to be safe leading to their widespread use."( Sparfloxacin-associated corneal epithelial toxicity.
Agarwal, AK; Ram, J; Singh, R, 2014
)
1.85

Pharmacokinetics

We looked for associations between pharmacokinetic (Pk) and pharmacodynamic (Pd) parameters of ciprofloxacin (CPFX) and sparfloxACin (SPFX) in an immunocompetent mouse model of severe Streptococcus pneumoniae pneumonia. Pharmacokinetic parameters (AUC(0-24) or C(max) were integrated with the pharmacodynamic parameter (MIC(90) to optimize sparfloxicin dosage in chicken.

ExcerptReferenceRelevance
" The pharmacokinetic analysis based on the physiological model indicated that fenbufen did not affect the permeability across the blood-brain or blood-CSF barrier."( Effect of fenbufen on the pharmacokinetics of sparfloxacin in rats.
Iwamoto, K; Katagiri, Y; Naora, K; Sekine, Y; Tanaka, K; Yamaguchi, T, 1992
)
0.54
"We studied the pharmacokinetic parameters of four fluoroquinolones--ofloxacin, ciprofloxacin, temafloxacin and sparfloxacin--in a mouse model of Streptococcus pneumoniae-infected lung."( Pharmacokinetics of four fluoroquinolones in an animal model of infected lung.
Azoulay-Dupuis, E; Bergogne-Bérézin, E; Pocidalo, JJ; Vallée, E, 1991
)
0.49
" The pharmacokinetics of AT-4140 may be characterized by its good tissue penetration and its long half-life in plasma and tissues."( Pharmacokinetics of a novel quinolone, AT-4140, in animals.
Hashimoto, M; Kurobe, N; Nakamura, S; Ohue, T; Shimizu, M, 1990
)
0.28
" Mean Cmax values ranged from 705 +/- 158 to 1966 +/- 620 ng/mL for the 200 to 800 mg doses, at median tmax ranging from 4 to 5 hours."( Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg.
Bruno, R; Chassard, D; Ebmeier, M; Frydman, A; Guimart, C; Le Roux, Y; Montay, G; Thebault, JJ; Vergniol, JC, 1994
)
0.61
" A significant relationship between pharmacokinetic parameters and creatinine clearance was observed only for renal clearance of parent or conjugated sparfloxacin."( Pharmacokinetics of sparfloxacin in patients with renal impairment.
Bruno, R; Dhib, M; Etienne, I; Fillastre, JP; Gay, G; Guimart, C; Le Roux, Y; Montay, G; Schott, D; Vivier, N, 1994
)
0.81
"In a randomized, double-blind, placebo-controlled, multiple-dose pharmacokinetic study, the safety and effect on intestinal flora of sparfloxacin (SPX) were determined in 12 healthy male volunteers (8 received SPX and 4 received a placebo)."( Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora.
Borner, K; Fassbender, M; Koeppe, P; Lode, H; Nord, CE; Ritz, M, 1994
)
0.77
" This is followed by a monophasic slow decrease, with an elimination half-life (t1/2) of 15 to 20 hours."( Clinical pharmacokinetics of sparfloxacin.
Ishibashi, Y; Nogita, T; Shimada, J, 1993
)
0.58
" No statistically significant differences were observed in the pharmacokinetic parameters (Cmax-AUC-T1/2-urinary excretion and metabolic ratio) of sparfloxacin following the 2 treatment."( Cimetidine does not alter sparfloxacin pharmacokinetics.
Alvarez, MP; Azanza, JR; Gries, JM; Honorato, J; Sadaba, B; Singlas, E; Taburet, AM, 1995
)
0.79
" Although such titers were not sufficient to predict a clinical response based on previous pharmacodynamic studies using quinolone antibiotics, data obtained with volunteers may only partially reflect the clinical situation in which a rise of humoral antibodies directed against pneumococcal antigens may help to reinforce the bactericidal action of the antibiotic."( Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci.
Borner, K; Koeppe, P; Ruhnke, M; Trautmann, M; Wagner, J, 1996
)
0.62
" Pharmacokinetic parameters were characterized with RSTRIP, an iterative, nonlinear, weighted, least-squares-regression program."( Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: physicochemical properties that regulate penetration of quinolone antimicrobials.
Drusano, G; Liu, QF; Liu, W; Louie, A; Madu, A; Mayers, M; Mian, U; Miller, MH; Perkins, R, 1998
)
0.62
"We looked for associations between pharmacokinetic (Pk) and pharmacodynamic (Pd) parameters of ciprofloxacin (CPFX) and sparfloxacin (SPFX) and the in vivo efficacy of these antimicrobials in an immunocompetent mouse model of severe Streptococcus pneumoniae pneumonia."( Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy.
Azoulay-Dupuis, E; Bédos, JP; Moine, P; Muffat-Joly, M; Pocidalo, JJ; Vallée, E; Veber, B, 1998
)
0.76
"A rapid and sensitive high-performance thin-layer chromatographic (HPTLC) method has been developed for the measurement of sparfloxacin in human plasma and its use for pharmacokinetic study has been evaluated."( High performance thin-layer chromatographic method for the determination of sparfloxacin in human plasma and its use in pharmacokinetic studies.
Gandhi, TP; Modi, IA; Modi, RI; Mody, VD; Pandya, KK; Satia, MC, 1998
)
0.74
"Sparfloxacin, a broad-spectrum, oral fluoroquinolone antimicrobial agent, has a long elimination half-life that permits once-daily administration."( Pharmacokinetic interaction of sparfloxacin and digoxin.
Conway, S; Dorr, MB; Hunt, TL; Johnson, RD; Talbot, GH, 1999
)
2.03
" The present study was undertaken to determine the effects of skim milk and a high-fat breakfast without milk on the single-dose pharmacokinetic characteristics of this antibiotic."( Effects of food on the pharmacokinetics of sparfloxacin.
Dorr, MB; Hunt, TL; Jensen, BK; Johnson, RD; Talbot, GH, 1999
)
0.57
" After each dose, serial blood samples and ECG measurements were obtained to determine the pharmacokinetic and pharmacodynamic variables for sparfloxacin."( The cardiac pharmacodynamics of therapeutic doses of sparfloxacin.
Dorr, MB; Hunt, T; Magner, D; Morganroth, J; Talbot, GH, 1999
)
0.75
" Because its single-dose pharmacokinetics are altered by renal impairment, the present study was undertaken to determine the effects of moderate or severe renal insufficiency on the multidose pharmacokinetic characteristics of and tolerance to sparfloxacin."( Pharmacokinetics of sparfloxacin in patients with renal impairment.
Dorr, MB; Jensen, B; Johnson, RD; Magner, D; Marbury, T; Talbot, GH, 1999
)
0.81
" After each dose, serial blood samples and ECG measurements were collected to determine sparfloxacin pharmacokinetic and pharmacodynamic variables."( The effect of terfenadine on the cardiac pharmacodynamics of sparfloxacin.
Dorr, MB; Hunt, T; Magner, D; Morganroth, J; Talbot, GH, 1999
)
0.77
"An in vitro pharmacokinetic model (IVPM) was used to simulate the human serum pharmacokinetics of moxifloxacin, levofloxacin and sparfloxacin, and to compare their pharmacodynamics against Streptococcus pneumoniae exhibiting a wide range of susceptibilities to fluoroquinolones."( Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.
Lister, PD; Sanders, CC, 2001
)
0.77
"This investigation explored pharmacodynamic characteristics of fluoroquinolones against Bacteroides thetaiotamicron and the potential for development of resistance."( Fluoroquinolone resistance in anaerobic bacteria following exposure to levofloxacin, trovafloxacin, and sparfloxacin in an in vitro pharmacodynamic model.
Hovde, LB; Peterson, ML; Ross, GH; Rotschafer, JC; Wright, DH, 2001
)
0.53
"The pharmacokinetics of ciprofloxacin and sparfloxacin were simulated in vitro and the effects of pharmacodynamic parameters on bactericidal activity and the emergence of quinolone resistance were examined for Streptococcus pneumoniae."( The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance.
Edwards, DI; Thorburn, CE, 2001
)
0.8
" In order to understand this difference in Vd(ss), first the contribution of each tissue to the Vd(ss) using pharmacokinetic parameters was estimated and it was found that the type of tissue contributing the most was muscle."( Determinant of the distribution volume at steady state for novel quinolone pazufloxacin in rats.
Hayakawa, H; Kawamura, Y; Takagi, K; Takano, YF; Tsuji, A, 2002
)
0.31
"05 microg/ml, which was sensitive enough for pharmacokinetic studies."( Improvement and validation of an HPLC method for examining the effects of the MDR1 gene polymorphism on sparfloxacin pharmacokinetics.
Cho, HY; Lee, YB; Park, SA, 2006
)
0.55
"Members of the fluoroquinolone class are being actively evaluated for inclusion in tuberculosis chemotherapy regimens, and we sought to determine the best in vitro and pharmacodynamic predictors of in vivo efficacy in mice."( Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
Balasubramanian, V; Bharath, S; Gaonkar, S; Jayaram, R; Jayashree, R; Kaur, P; Mahesh, BN; Nandi, V; Shandil, RK; Suresh, BL, 2007
)
0.64
" The pharmacokinetic parameters (AUC(0-24) or C(max)) were integrated with the pharmacodynamic parameter (MIC(90)) to optimize sparfloxacin dosage in chicken."( Pharmacokinetics of sparfloxacin in broiler chicken.
Kalaiselvi, L; Mathuram, LN; Ramesh, S; Sriram, P; Sriranjani, D, 2006
)
0.86
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The developed assay method was applied to a pharmacokinetic study in human volunteers following oral administration of 400 mg GFC tablet."( Development and validation of a HPLC method for simultaneous quantitation of gatifloxacin, sparfloxacin and moxifloxacin using levofloxacin as internal standard in human plasma: application to a clinical pharmacokinetic study.
Mullangi, R; Narasu, L; Shankar, BP; Srinivas, N, 2008
)
0.57

Compound-Compound Interactions

Sparfloxacin was used to treat experimental endocarditis in rabbits caused by ampicillin-resistant enterococci.

ExcerptReferenceRelevance
"Sparfloxacin and clinafloxacin alone and in combination with gentamicin, were evaluated for the treatment of experimental endocarditis in rabbits caused by ampicillin-resistant enterococci."( Sparfloxacin and clinafloxacin alone or in combination with gentamicin for therapy of experimental ampicillin-resistant enterococcal endocarditis in rabbits.
Donabedian, SA; Perri, MB; Thal, LA; Vazquez, J; Zervos, MJ, 1993
)
3.17
"Ten clinical isolates of Streptococcus pneumoniae (six intermediately penicillin-sensitive, one penicillin-resistant and three penicillin-sensitive strains) were studied by kill-kinetic experiments using sparfloxacin alone and in combination with amoxicillin."( Bactericidal effect of sparfloxacin alone and in combination with amoxicillin against Streptococcus pneumoniae as determined by kill-kinetic studies.
Barakett, V; Delisle, F; Lesage, D; Petit, JC; Richard, G,
)
0.63
" It is concluded that DU-6859a and trovafloxacin are very potent against enterococci, especially when combined with gentamicin."( In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.
Giamarellos-Bourboulis, EJ; Giamarellou, H; Grecka, P; Sambatakou, H, 1998
)
0.3
"To study the efficacy and safety of sparfloxacin, in combination with kanamycin (for the initial 3-4 months) and ethionamide, in multidrug-resistant (MDR) pulmonary tuberculosis patients."( Efficacy and safety of sparfloxacin in combination with kanamycin and ethionamide in multidrug-resistant pulmonary tuberculosis patients: preliminary results.
Arora, VK; Gupta, R; Gupta, S; Singla, R, 2001
)
0.9
"Convulsant activity of pazufloxacin mesilate (PZFX mesilate), a new quinolone antibacterial agent for intravenous use, in combination with nonsteroidal anti-inflammatory drug (NSAID) was investigated in mice after intravenous or intracerebroventricular administration."( [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
Fukuda, H; Kawamura, Y, 2002
)
0.31

Bioavailability

Sparfloxacin bioavailability with increasing dose was observed. AUC was 87% to 88% of the expected area when the dose was doubled. Coadministration of sucralfate leads to a 44% decrease in the bioavailability of sparfl Oxacin. Antacids containing aluminium hydroxide reduce the oral bioavailability by 25 to 35%.

ExcerptReferenceRelevance
" The oral bioavailability of AT-4140 calculated from the ratio of the areas under the concentration-time curve after oral and intravenous administration was 77% in dogs."( Pharmacokinetics of a novel quinolone, AT-4140, in animals.
Hashimoto, M; Kurobe, N; Nakamura, S; Ohue, T; Shimizu, M, 1990
)
0.28
" These results confirmed that the addition of L-HPC to the cores increases not only the dissolution rate but also the bioavailability of SPFX."( Role of low-substituted hydroxypropylcellulose in dissolution and bioavailability of novel fine granule system for masking bitter taste.
Fujioka, H; Nakamura, Y; Shirai, Y; Sogo, K, 1994
)
0.29
" A slight decrease of sparfloxacin bioavailability with increasing dose was observed because AUC was 87% to 88% of the expected area when the dose was doubled."( Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg.
Bruno, R; Chassard, D; Ebmeier, M; Frydman, A; Guimart, C; Le Roux, Y; Montay, G; Thebault, JJ; Vergniol, JC, 1994
)
0.93
" Antacids containing aluminium hydroxide reduce the oral bioavailability of sparfloxacin by 25 to 35%."( Clinical pharmacokinetics of sparfloxacin.
Ishibashi, Y; Nogita, T; Shimada, J, 1993
)
0.81
" The bioavailability of the film-coated fine granules containing 20% SPFX and 52% L-HPC in the cores and 10% EC/HPMC (4/2) in the coating film, which masked the bitter taste of SPFX and showed the optimal release characteristics, was equivalent to that of conventional tablets containing 100 mg SPFX in beagle dogs."( A novel fine granule system for masking bitter taste.
Fujioka, H; Kojima, K; Makita, H; Nakamura, Y; Shirai, Y; Sogo, K; Yamamoto, K, 1993
)
0.29
" The reduction in bioavailability of fluoroquinolones by concurrent administration of aluminium hydroxide is more striking for derivatives with fewer substituents on the essential structure and on the piperazinyl group, such as norfloxacin, ciprofloxacin and enoxacin."( Pharmacokinetic interactions related to the chemical structures of fluoroquinolones.
Fujiwara, I; Mizuki, Y; Yamaguchi, T, 1996
)
0.29
" Coadministration of sucralfate leads to a 44% decrease in the bioavailability of sparfloxacin."( Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.
Borner, K; Geerdes-Fenge, HF; Koeppe, P; Lode, H; Rau, M; Vöckler, J; Zix, JA, 1997
)
0.85
" It is well absorbed and has excellent penetration into upper and lower respiratory tissues."( Sparfloxacin: potential clinical and economic impact in the treatment of respiratory infections.
Havlichek, DH; Stein, GE,
)
1.57
" The relative bioavailability of sparfloxacin was 84."( Sparfloxacin pharmacokinetics in healthy volunteers: the influence of acidification and alkalinization.
Kamberi, M; Kotegawa, T; Nakamura, K; Nakano, S; Tsutsumi, K, 1998
)
2.02
" On the other hand, the alteration in the environmental pH in the gastrointestinal tract, produced by the concomitant ingestion of ammonium chloride or sodium bicarbonate, influences the absorption and bioavailability of sparfloxacin."( Sparfloxacin pharmacokinetics in healthy volunteers: the influence of acidification and alkalinization.
Kamberi, M; Kotegawa, T; Nakamura, K; Nakano, S; Tsutsumi, K, 1998
)
1.93
" Antibiotics may increase the oral bioavailability of digoxin, leading to increases in its plasma concentration."( Pharmacokinetic interaction of sparfloxacin and digoxin.
Conway, S; Dorr, MB; Hunt, TL; Johnson, RD; Talbot, GH, 1999
)
0.59
" At supratherapeutic doses, the extent of sparfloxacin's absorption (AUC0-infinity) was dose independent; however, the rate of absorption was dose dependent, with Cmax increasing substantially less than proportionally to the administered dose."( Effect of single ascending, supratherapeutic doses of sparfloxacin on cardiac repolarization (QTc interval).
Dorr, MB; Geary, W; Johnson, RD; Magner, D; Morganroth, J; Talbot, GH, 1999
)
0.82
" Despite the apparent delay in the onset of absorption, the bioavailability of sparfloxacin in the healthy male subjects in this study population was not affected by concomitant administration with skim milk or a high-fat meal."( Effects of food on the pharmacokinetics of sparfloxacin.
Dorr, MB; Hunt, TL; Jensen, BK; Johnson, RD; Talbot, GH, 1999
)
0.79
" Oral bioavailability was 61."( Pharmacokinetics of sparfloxacin in broiler chicken.
Kalaiselvi, L; Mathuram, LN; Ramesh, S; Sriram, P; Sriranjani, D, 2006
)
0.66
"Poor ocular bioavailability of drugs (<1%) from conventional eye drops (ie, solution, suspension, and ointments) is mainly due to the physiologic barriers of the eye."( Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery.
Ali, A; Aqil, M; Bhatnagar, A; Gupta, H; Khar, RK; Mittal, G, 2010
)
1.8
"Poor ocular bioavailability of drugs (<1%) from conventional eye drops is mainly due to the eye physiological barriers."( Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery.
Ali, A; Aqil, M; Bhatnagar, A; Gupta, H; Khar, RK; Mittal, G, 2010
)
1.8
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010
)
0.36
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" However, the major problem encountered in these dosage forms is precorneal elimination of the drug, resulting in poor bioavailability and therapeutic response."( Development and evaluation of a novel in situ gel of sparfloxacin for sustained ocular drug delivery: in vitro and ex vivo characterization.
Ali, A; Aqil, M; Imam, SS; Khan, N, 2015
)
0.67
", solubility in an aqueous medium and lipophilic properties, which have an effect on the bioavailability of five selected fluoroquinolones."( Experimental and theoretical studies on the molecular properties of ciprofloxacin, norfloxacin, pefloxacin, sparfloxacin, and gatifloxacin in determining bioavailability.
Betlejewska-Kielak, K; Biernacka, J; Grudzień, M; Kłosińska-Szmurło, E; Mazurek, AP; Pluciński, FA, 2014
)
0.62
" Increased selective accumulation in active neoplasm with simultaneous enhanced bioavailability and reduced systemic toxicity of liposomal formulation of copper(i) complexes can result in the development of new copper-based therapeutics and their successful implementation in anticancer chemotherapy."( Copper(i) complexes with phosphine derived from sparfloxacin. Part III: multifaceted cell death and preliminary study of liposomal formulation of selected copper(i) complexes.
Cierniak, A; Gubernator, J; Jeżowska-Bojczuk, M; Komarnicka, UK; Kyzioł, A; Markowski, A, 2018
)
0.74
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The studies show that complexation with famotidine or ranitidine may affect the bioavailability of sparfloxacin."( Simultaneous interaction, degradation, and kinetic study of sparfloxacin with H2 receptor antagonist.
Amir Hassan, -; Fouzia Shafi, -; Iffat Sultana, -; Maria Qureshi, -; Nazia Tabassum, -; Qurat Ul Aen Ismail, -; Sadia Iqbal, -; Shereen, -; Sohail Hassan, -; Tahreem Mujtaba, -, 2023
)
1.37

Dosage Studied

A once-daily dosage of sparfloxacin should be adequate to treat systemic infections caused by most common bacterial pathogens. SparfloxACin was more effective than levofloxac in both dosing regimens.

ExcerptRelevanceReference
" By serial dosing (once a day, 5 or 6 times per week, during the 3rd-5th months postinoculation), 10 mg/kg of sparfloxacin displayed bactericidal-type activity and bacteriostatic activity was present at daily doses of 5 and 2 mg/kg."( Activity of sparfloxacin against Mycobacterium leprae inoculated into footpads of nude mice.
Gidoh, M; Tsutsumi, S, 1992
)
0.87
" Our results indicate that a once-daily dosage of sparfloxacin should be adequate to treat systemic infections caused by most common bacterial pathogens."( Pharmacokinetics and inflammatory fluid penetration of sparfloxacin.
Andrews, JM; Cooper, MA; Johnson, JH; Wise, R, 1992
)
0.78
" leprae; temafloxacin and sparfloxacin were the most active, being fully bactericidal at all three dosage schedules."( Activities of various quinolone antibiotics against Mycobacterium leprae in infected mice.
Gelber, RH; Iranmanesh, A; Murray, L; Siu, P; Tsang, M, 1992
)
0.58
" tuberculosis H37Rv strain, the minimal effective dosage of sparfloxacin, as assessed by survival rate, spleen enlargement and gross lung lesions, was 12."( In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis.
Grosset, J; Ji, B; Truffot-Pernot, C, 1991
)
0.8
" Within 48 h, about half of the dosed radioactivity was excreted in the bile, and part of which was re-absorbed."( Disposition and metabolism of [14C]sparfloxacin in the rat.
Furukawa, H; Hashimoto, M; Matsunaga, Y; Miyazaki, H; Nambu, K; Oh-e, Y; Yoshida, K, 1991
)
0.56
" It seems, therefore, that the in vivo activity of LVFX is comparable to that produced by a twofold-greater dosage of OFLO."( In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.
Grosset, J; JI, B; Lounis, N; Truffot-Pernot, C, 1995
)
0.29
" In a dose-response study, treatment with LEV at 100, 200, and 400 mg/kg of body weight was started 1 day after infection and was given daily for 28 days."( Activity of levofloxacin in a murine model of tuberculosis.
Cynamon, MH; Klemens, SP; Rogge, MC; Sharpe, CA, 1994
)
0.29
" Sparfloxacin was more effective than levofloxacin and ofloxacin in both dosing regimens."( In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.
Irifune, K; Ishida, K; Kaku, M; Mizukane, R; Suyama, N; Takemura, H; Tanaka, H; Tomono, K; Usui, T; Yoshida, R, 1994
)
1.48
" These results, together with pharmacokinetic and toxicological data in mice and man, suggest that sparfloxacin may have a higher therapeutic index than ofloxacin in leprosy, and that the tentative standard dosage of 200 mg sparfloxacin daily should be appropriate for a clinical trial."( Sparfloxacin is more bactericidal than ofloxacin against Mycobacterium leprae in mice.
Chan, GP; Franzblau, SG; Parrilla, ML, 1993
)
1.95
" Studies in patients show that the pharmacokinetics of sparfloxacin were not influenced by age but severe renal failure markedly impaired elimination of the parent drug (the T1/2 was approximately doubled in patients with renal failure), and glucuronide, requiring adjustment of the dosage regimen."( Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review.
Montay, G, 1996
)
0.86
" Its long elimination half-life permits once-daily dosage regimens."( Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.
Bryson, HM; Goa, KL; Markham, A, 1997
)
1.74
" Clinafloxacin at higher dosage (45 mg/kg/d) resulted in a decrease in myeloid progenitors in BM."( Enhanced hematopoiesis in sublethally irradiated mice treated with various quinolones.
Fabian, I; Gruss, T; Kletter, Y; Shalit, I; Weiss, K, 1997
)
0.3
" In addition, a constant dosage of SPFX and SYN 1193, in combination with varying dosages of erythromycin, was tested under similar experimental conditions."( The effects of macrolide and quinolone antibiotics in methicillin-resistant Staphylococcus aureus biofilm growth.
Dasgupta, MK; Larabie, M; Micetich, RG; Salama, S; Shishido, H; Singh, R, 1997
)
0.3
"The objective of this randomized, double-blind, multicenter study of 329 adult patients requiring hospitalization was to compare the safety and efficacy of sparfloxacin at a dosage of 200 mg once daily (following a 400-mg loading dose on day 1) with those of amoxicillin given as a 1-g oral dose three times daily for treatment of community-acquired pneumonia suspected to be due to Streptococcus pneumoniae."( Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group.
Aubier, M; Geslin, P; Regamey, C; Vercken, JB; Verster, R, 1998
)
0.89
" The impact of the dosing interval on the antimicrobial dose response was evaluated based on the survival of mice treated for 3 days with CPFX (25-200 mg/kg) or SPFX (6."( Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy.
Azoulay-Dupuis, E; Bédos, JP; Moine, P; Muffat-Joly, M; Pocidalo, JJ; Vallée, E; Veber, B, 1998
)
0.56
" Multiple dosing and long-term treatment with sparfloxacin seems to induce a mutation in ParC and an alteration leading to reduced drug accumulation that contribute to increasing the fluoroquinolone resistance level."( Analysis of quinolone resistance mechanisms in a sparfloxacin-resistant clinical isolate of Neisseria gonorrhoeae.
Haraoka, M; Kobayashi, I; Nagafuji, T; Nakayama, H; Saika, T; Tanaka, M, 1998
)
0.81
" This study was undertaken to determine an optimal time for dosing antacids in relation to sparfloxacin administration to minimize antacid-induced reduction in sparfloxacin bioavailability."( Effect of Maalox on the oral absorption of sparfloxacin.
Caille, G; Dorr, MB; Johnson, RD; Talbot, GH,
)
0.61
"This double-masked, randomized, placebo-controlled study assessed the cardiac safety of sparfloxacin (as measured by the effect on corrected QT [QTc] interval) at the extremes of the expected therapeutic dosage range."( The cardiac pharmacodynamics of therapeutic doses of sparfloxacin.
Dorr, MB; Hunt, T; Magner, D; Morganroth, J; Talbot, GH, 1999
)
0.78
" Mean steady-state plasma sparfloxacin concentrations in subjects with severe renal insufficiency (48-hour dosing interval) were comparable to those in subjects with normal renal function (24-hour dosing interval)."( Pharmacokinetics of sparfloxacin in patients with renal impairment.
Dorr, MB; Jensen, B; Johnson, RD; Magner, D; Marbury, T; Talbot, GH, 1999
)
0.93
"To investigate the effect of sucralfate on sparfloxacin absorption when administered concurrently or at strategically spaced dosing times designed to avoid the potential interaction."( The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.
Kamberi, M; Nakano, S; Nakashima, H; Oda, N; Ogawa, K, 2000
)
0.8
" pneumoniae, with standard dosing resulting in area under the concentration-time curve/MIC ratios and peak concentration/MIC ratios that resulted in 99."( Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Hershberger, E; Rybak, MJ, 2000
)
0.55
" Dose-response experiments with two topoisomerase IV mutants that confer clinical resistance to quinolones (GrlA(Ser80Phe) and GrlA(Glu84Lys)) indicate that resistance is caused by a decrease in both drug affinity and efficacy."( Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
Anderson, VE; Gootz, TD; Kaczmarek, FS; Osheroff, N; Zaniewski, RP, 2000
)
0.31
" In contrast, pneumococci with a two- to four-fold increase in sparfloxacin MIC were selected in the presence of serum concentrations of sparfloxacin despite a C(max)/MIC ratio higher than 12, but these isolates remained clinically susceptible by breakpoint MIC and their growth was inhibited by repeated dosage of sparfloxacin."( The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance.
Edwards, DI; Thorburn, CE, 2001
)
0.78
" In addition, concurrent dosing of BPAA (1 microgram/body) did not reduce the convulsion-inducing dose of PZFX mesilate."( [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
Fukuda, H; Kawamura, Y, 2002
)
0.31
" In a second study, two dosage regimens of sitafloxacin were compared with placebo in Oriental subjects."( A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity.
Dawe, RS; Ferguson, J; Ibbotson, SH; Sanderson, JB; Thomson, EM, 2003
)
0.54
" Dosing was discontinued in two patients because of pruritic skin eruptions."( Antibacterial activity and clinical efficacy of sparfloxacin in Mycobacterium avium-intracellulare complex infection.
Handa, M; Horiguchi, T; Kondo, R; Miyazaki, J; Munekata, E; Shiga, M; Sugiyama, M,
)
0.39
" First of all, to obtain an optimum dosage level for induction of phototoxicity, the prototype phototoxicant sparfloxacin was intravenously administered once at 10 mg/kg, 30 mg/kg or 100 mg/kg to female mice, followed immediately by ultraviolet-A (UVA) irradiation for 4 h (21."( Structure-phototoxicity relationship in Balb/c mice treated with fluoroquinolone derivatives, followed by ultraviolet-A irradiation.
Furuhama, K; Goto, K; Jindo, T; Sekiguchi, M; Yabe, K, 2005
)
0.54
" The method was applied to the determination of LFX, SFX and GFX in dilute urine samples and dosage forms, and compared with the HPLC method."( Electrochemical adsorptive behavior of some fluoroquinolones at carbon paste electrode.
Abdel Ghani, NT; El Ries, MA; El-Shall, MA; Wassel, AA, 2005
)
0.33
" The proposed methods were also applied for the determination of the investigated drugs in their pharmaceutical dosage forms and their validity was assessed using the standard addition technique with mean percentage recovery ranging from 100."( Stability indicating methods for the determination of some fluoroquinolones in the presence of their decarboxylated degrades.
Abd-El-Fattah, Lel-S; El-Guindi, NM; Mikael, HK; Salem, MY, 2006
)
0.33
" The pharmacokinetic parameters (AUC(0-24) or C(max)) were integrated with the pharmacodynamic parameter (MIC(90)) to optimize sparfloxacin dosage in chicken."( Pharmacokinetics of sparfloxacin in broiler chicken.
Kalaiselvi, L; Mathuram, LN; Ramesh, S; Sriram, P; Sriranjani, D, 2006
)
0.86
" The method was found selective for determination of sparfloxacin in the presence of commonly used excipients in dosage forms."( Quantification of sparfloxacin in pharmaceutical dosages and biological samples.
Jan, MR; Khan, I; Khan, MN; Shah, J, 2012
)
0.96
" However, the major problem encountered in these dosage forms is precorneal elimination of the drug, resulting in poor bioavailability and therapeutic response."( Development and evaluation of a novel in situ gel of sparfloxacin for sustained ocular drug delivery: in vitro and ex vivo characterization.
Ali, A; Aqil, M; Imam, SS; Khan, N, 2015
)
0.67
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (5)

ClassDescription
quinolone
quinolinemonocarboxylic acidAny aromatic carboxylic acid that contains a quinoline moiety that is substituted by one carboxy substituent.
N-arylpiperazine
quinolone antibioticAn organonitrogen heterocyclic antibiotic whose structure contains a quinolone or quinolone-related skeleton.
fluoroquinolone antibioticAn organonitrogen heterocyclic antibiotic containing a quinolone (or quinolone-like) moiety and which have a fluorine atom attached to the central ring system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency22.01630.003245.467312,589.2998AID2517
TDP1 proteinHomo sapiens (human)Potency20.25200.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency21.13170.000221.22318,912.5098AID743040
EWS/FLI fusion proteinHomo sapiens (human)Potency10.22320.001310.157742.8575AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency7.56240.000214.376460.0339AID720691
estrogen nuclear receptor alphaHomo sapiens (human)Potency5.35380.000229.305416,493.5996AID743075
DNA polymerase betaHomo sapiens (human)Potency44.66840.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency4.46680.039816.784239.8107AID1454
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)IC50 (µMol)88.80000.00032.63119.0000AID1207773
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)IC50 (µMol)47.13840.00001.612910.0000AID625171
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)Ki38.61940.00042.03378.6606AID625171
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)IC50 (µMol)34.30000.00051.33138.0000AID755687; AID755690
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)IC50 (µMol)88.80000.00032.59559.0000AID1207773
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)66.89530.00091.901410.0000AID161281; AID243151; AID243188; AID408340; AID420668; AID51936; AID625171; AID755684; AID755685; AID755686; AID755687; AID755688; AID755689; AID755690
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)Ki38.61940.00211.840710.0000AID625171
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)IC50 (µMol)88.80000.00032.63119.0000AID1207773
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)88.80000.00032.25459.6000AID1207773
Nuclear receptor subfamily 3 group C member 3 Bos taurus (cattle)IC50 (µMol)47.13840.10482.83988.3173AID625171
Nuclear receptor subfamily 3 group C member 3 Bos taurus (cattle)Ki38.61940.08582.95428.6606AID625171
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)INH966.00007.40007.40007.4000AID1723736
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (103)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
detection of light stimulus involved in visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
sensory perception of soundVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion importVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transporter activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
skeletal system developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
extraocular skeletal muscle developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
striated muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
endoplasmic reticulum organizationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
myoblast fusionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
neuromuscular junction developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle adaptationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle fiber developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
release of sequestered calcium ion into cytosolVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cellular response to caffeineVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (47)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
ankyrin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
small molecule bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
molecular function activator activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (32)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
photoreceptor outer segmentVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
sarcoplasmic reticulumVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
T-tubuleVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
I bandVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (615)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID556865Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 5 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID450457Antibacterial activity against Staphylococcus aureus after 24 hrs by twofold serial dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Interaction of drug based binuclear mixed-ligand complexes with DNA.
AID395717Antibacterial activity against Escherichia coli DH10B containing ORI23 promoter by twofold dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID556668Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 23 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID206284In vitro antibacterial activity against Staphylococcus aureus 507741990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID94001Antibacterial activity was determined against gram negative organism, Klebsiella pneumoniae MGH-21991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID94147In vitro antibacterial activity against gram negative Klebsiella pneumoniae MGH-2.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID1557288Antibacterial activity against Clostridium perfringens by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID23546Aqueous solubility1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID556669Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 24 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1297673Hemolytic activity against human RBC at 0.19 to 3.9 mg/L after 1 hr relative to control2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones.
AID260741Antibacterial activity against Enterococcus faecalis 292122006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.
AID561399Antibacterial activity against quinolone-susceptible Bordetella pertussis BP117 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Emergence of quinolone-resistant Bordetella pertussis in Japan.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID53317Iinhibitory activity against Escherichia coli DNA gyrase2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID556863Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 3 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID69597Antibacterial activity was evaluated against Escherichia coli2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
AID197882Antibacterial activity was determined against gram positive organism, Staphylococcus aureus UC761991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID556888Antimicrobial activity against multidrug resistant Klebsiella pneumoniae ATCC 11296 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID556869Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 9 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID544836Antibacterial activity against Streptococcus pneumoniae U2A1050 harboring gyrA Ser81Phe mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID561388Antibacterial activity against quinolone-susceptible Bordetella pertussis CCUG 30837 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Emergence of quinolone-resistant Bordetella pertussis in Japan.
AID1297668Bacteriostatic activity against Staphylococcus aureus 209p measured every 24 hrs for 5 days by broth dilution method2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones.
AID434858Antibacterial activity against multidrug-resistant Pseudomonas aeruginosa after 24 hrs by broth microdilution method2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Microwave assisted synthesis of new indophenazine 1,3,5-trisubstruted pyrazoline derivatives of benzofuran and their antimicrobial activity.
AID1600094Lipophilicity, log k of the compound at 100 ug/ml by micellar electrokinetic chromatography2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1557303Cmax in human at 0.4 g, po2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID544857Antibacterial activity against Streptococcus pneumoniae U2A1266 harboring gyrA Ser81Cys mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID295342Antibacterial activity against Staphylococcus aureus ATCC 137092007Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10
Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains.
AID1393819Antibacterial activity against Mycobacterium smegmatis by NCCLS method2018European journal of medicinal chemistry, Feb-25, Volume: 146Fluoroquinolone derivatives and their anti-tubercular activities.
AID237458Partition coefficient (logD7.4)2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID298863Antibacterial activity against Klebsiella pneumoniae ATCC 10031 by micro-broth dilution method2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID556874Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 14 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID406845Antibacterial activity against Escherichia coli TOP10 containing pS1B plasmid expressing quinolone resistance determinant QnrS1 by E-test2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant.
AID1557284Antibacterial activity against Staphylococcus aureus by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID556680Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 7 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID165035In vitro antibacterial activity against Pseudomonas aeruginosa 121990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID556671Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 26 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID117690The in vivo potency was determined in female charles river CD-1 mice infected with Streptococcus pneumoniae after sc administration1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID260740Antibacterial activity against methicillin resistant Staphylococcus aureus MRSA 10942006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.
AID556649Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 4 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID295345Antibacterial activity against ciprofloxacin resistant methicillin resistant Staphylococcus aureus OC39462007Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10
Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains.
AID544867Antibacterial activity against Streptococcus pneumoniae U2A1060 harboring gyrA Ser81Phe parC Asp83His mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID391989Antibacterial activity against Lactococcus lactis IL-1419 by twofold dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID1600102Bactericidal activity against Enterococcus hirae ATCC 1052 cultured in BHI medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID556893Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 5 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID298860Antibacterial activity against Staphylococcus aureus ATCC 33591 by micro-broth dilution method2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.
AID368419Antimicrobial activity against Escherichia coli KAM32 expressing deltaacrB ydhE hsd gene by agar dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID678910TP_TRANSPORTER: increase in Doxorubicin intracellular accumulation (Doxorubicin: 5 uM, SPFX: 500 uM) in P388/ADR cells2002Clinical and experimental pharmacology & physiology, Mar, Volume: 29, Issue:3
Possible involvement of P-glycoprotein in the biliary excretion of grepafloxacin.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID556664Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 19 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID406847Antibacterial activity against Enterobacter cloacae S1 isolate expressing quinolone resistance determinant QnrB4 by E-test2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant.
AID1600106Bactericidal activity against Escherichia coli ATCC 8739 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1600096Bactericidal activity against Staphylococcus aureus ATCC 6538 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID64404The in vivo potency was determined in female charles river CD-1 mice infected with Escherichia coli after peroral administration1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID679029TP_TRANSPORTER: inhibition of DNP-SG uptakee (DNP-SG: 1 uM, SPFX: 3000 uM) in bile canalicular membrane vesicles from SD rat1998The Journal of pharmacology and experimental therapeutics, Mar, Volume: 284, Issue:3
Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats.
AID544864Antibacterial activity against Streptococcus pneumoniae U2A1681 harboring parC Ser79Tyr Asp83Ala mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID96249In vitro antibacterial activity against Klebsiella pneumoniae 131990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID209122Anti-bacterial activity tested against Gram-positive SP1-1 bacterium1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.
AID279826Cmax in BALB/c mouse at 5 to 1000 mg/kg, po2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID522874Antibacterial activity against uropathogenic Escherichia coli UTI89 infected in human 5637 cells assessed as decrease in intracellular bacterial level at 12 to 100 ug/ml after 12 hrs by serial dilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
AID324751Antibacterial activity in Mycobacterium leprae infected mouse foot-pad model assessed as parasite killing at 15 mg/kg/day after 9 months2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID295346Antibacterial activity against ciprofloxacin resistant methicillin resistant Staphylococcus aureus OC41592007Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10
Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains.
AID557081Antimicrobial activity against multidrug resistant Escherichia coli DH5[alpha] harboring pACM204 plasmid by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID556658Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 13 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID206876Antibacterial activity against Staphylococcus aureus FDA 209P2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID144719In vito growth of Mycobacterium tuberculosis BC-426 strain after 6 weeks; - indicates no growth2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Synthesis of galactopyranosyl amino alcohols as a new class of antitubercular and antifungal agents.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID163111Minimum inhibitory concentration against gram-negative Pseudomonas aeruginosa U1-18 (PA-7)1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria.
AID74734MIC ratio measured as the mean MICs of gram-positive bacteria1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID339997Binding affinity to calf thymus DNA2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Structure, antimicrobial activity and DNA-binding properties of the cobalt(II)-sparfloxacin complex.
AID298866Antibacterial activity against Staphylococcus aureus ATCC 29213 by micro-broth dilution method2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.
AID556691Antimicrobial activity against multidrug resistant Enterobacter aerogenes ATCC 15038 harboring pDrive plasmid by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1600113Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 13199 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID530598Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr10 carrying Smqnr gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID66899Antibacterial activity against Enterococcus faecalis KU1777 (VRE)2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID144717In vito growth of Mycobacterium tuberculosis BC-248 strain after 6 weeks; - indicates no growth2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Synthesis of galactopyranosyl amino alcohols as a new class of antitubercular and antifungal agents.
AID268190Antimicrobial activity against Pseudomonas aeruginosa2006Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14
Crystal structure, spectroscopic, and biological study of the copper(II) complex with third-generation quinolone antibiotic sparfloxacin.
AID544862Antibacterial activity against Streptococcus pneumoniae U2A1693 harboring parC Asp83Asn mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID723106Antibacterial activity against Enterobacter aerogenes CM-64 overexpressing AcrAB-TolC assessed as growth inhibition after 18 hrs by CLSI broth dilution method2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Search for new tools to combat Gram-negative resistant bacteria among amine derivatives of 5-arylidenehydantoin.
AID556886Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 26 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID268189Antimicrobial activity against Escherichia coli2006Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14
Crystal structure, spectroscopic, and biological study of the copper(II) complex with third-generation quinolone antibiotic sparfloxacin.
AID143596Minimum inhibitory concentration against Mycobacterium fortuitum1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria.
AID556690Antimicrobial activity against multidrug resistant Enterobacter aerogenes ATCC 15038 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID324747Antibacterial activity against Mycobacterium leprae at 5 ug/mL after 11 to 18 days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID1557283Antibacterial activity against Haemophilus influenzae with horse blood by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID556694Antimicrobial activity against multidrug resistant Escherichia coli DH5[alpha] by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID157244In vitro antibacterial activity was tested for Pepto asac PA 3-11995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID522861Antibacterial activity against uropathogenic Escherichia coli UTI89 infected in CBA/J mouse assessed as decrease in bacterial invasion into layers of urothelium at 700 ug/kg, po administered on day 3 postinfection daily for 3 days measured on day 9 post-i2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID556662Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 17 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID143597Minimum inhibitory concentration against Mycobacterium smegmatis1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria.
AID556672Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 27 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID556670Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 25 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID118113Phototoxic skin reaction in depilated female CD-1 mice1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID530589Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr1 carrying Smqnr gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID298861Antibacterial activity against Enterococcus faecalis ATCC 29212 by micro-broth dilution method2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.
AID41263In vitro antibacterial activity against Bacteroides fragilis BFA1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID1129361Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
AID1164302Inhibition of RNA synthesis in Mycobacterium bovis BCG assessed as inhibition of [3H]uracil incorporation by liquid scintillation counting2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis.
AID260738Antibacterial activity against Staphylococcus aureus 252932006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.
AID556879Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 19 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID575054Antibacterial activity against Vibrio cholerae O1 569B harboring gyrA and parC genes by 2-fold agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Reduced expression of the vca0421 gene of Vibrio cholerae O1 results in innate resistance to ciprofloxacin.
AID69623Antibacterial activity against Escherichia coli NIHJ JC-22004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID755687Binding affinity to human ERG S624A tetrameric mutant expressed in HEK293 cells assessed as inhibition of tail current measured upon repolarization to -40 mV by patch clamp method2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
AID544837Antibacterial activity against Streptococcus pneumoniae U2A1051 harboring gyrA Ser81Tyr mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID56394Iinhibitory activity against Staphylococcus aureus DNA topoisomerase IV2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID206879Antibacterial activity against Staphylococcus aureus N1752004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID260736Binding affinity to Bacillus subtilis DNA polymerase3C2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.
AID1600097Antibacterial activity against methicillin resistant Staphylococcus aureus N315 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID544860Antibacterial activity against Streptococcus pneumoniae U2A1053 harboring parC Ser79Phe mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID50999In vitro antibacterial activity against Clostridium perfringens CP 3-11995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID201273In vitro antibacterial activity against gram positive Staphylococcus aureus H-228.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID206728Antibacterial activity was evaluated against Staphylococcus aureus2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
AID1723736Inhibition of human ERG by whole-cell patch clamp method2020Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections.
AID295341Antibacterial activity against Escherichia coli KL162007Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10
Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains.
AID434850Antibacterial activity against multidrug-resistant Staphylococcus aureus after 24 hrs by broth microdilution method2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Microwave assisted synthesis of new indophenazine 1,3,5-trisubstruted pyrazoline derivatives of benzofuran and their antimicrobial activity.
AID406846Antibacterial activity against Escherichia coli TOP10 containing pS1A plasmid expressing quinolone resistance determinant QnrB4 by E-test2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant.
AID548255Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSn mutant gene after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID556683Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 10 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID395715Antibacterial activity against Lactococcus lactis IL-1419 containing ORI23::qnr-cat promoter mutant by twofold dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID481439Absolute bioavailability in human2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID548475Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm, graRm mutant gene after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID279845Drug level in Mycobacterium tuberculosis infected BALB/c mouse model at 31 to 50000 mg/kg, po2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID680109TP_TRANSPORTER: increase in brain concentration in mdr1a/1b(-/-) mouse2000The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1
Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier.
AID561402Antibacterial activity against quinolone-susceptible Bordetella pertussis BP122 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Emergence of quinolone-resistant Bordetella pertussis in Japan.
AID144009Anti-bacterial activity tested against Mycobacterium fortuitum (ATCG 6841)1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.
AID237034Dissociation constant (pKa) was determined2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID1297669Bactericidal activity against Bacillus cereus 8035 incubated for 4 hrs2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones.
AID574811Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis H37Rv by CLSI method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID548256Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm mutant gene after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID556681Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 8 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID237037Dissociation constant (pKa) was determined2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID556895Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 7 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID556866Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 6 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID556899Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 11 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID544859Antibacterial activity against Streptococcus pneumoniae R6 Tr1 harboring parC Ser79Tyr mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID206679Antibacterial activity against Staphylococcus pneumoniae ATCC 496192004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID556663Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 18 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID434852Antibacterial activity against multidrug-resistant Salmonella typhi after 24 hrs by broth microdilution method2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Microwave assisted synthesis of new indophenazine 1,3,5-trisubstruted pyrazoline derivatives of benzofuran and their antimicrobial activity.
AID450461Antibacterial activity against Escherichia coli after 24 hrs by twofold serial dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Interaction of drug based binuclear mixed-ligand complexes with DNA.
AID1297670Bactericidal activity against Staphylococcus aureus 209p incubated for 4 hrs2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones.
AID434854Antibacterial activity against multidrug-resistant Streptococcus agalactiae after 24 hrs by broth microdilution method2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Microwave assisted synthesis of new indophenazine 1,3,5-trisubstruted pyrazoline derivatives of benzofuran and their antimicrobial activity.
AID556659Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 14 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID66898Antibacterial activity against Enterococcus faecalis ATCC 292122004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID69620Antibacterial activity against Escherichia coli K 9012004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID556892Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 4 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1600115Antibacterial activity against Streptococcus pneumoniae cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID556890Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 2 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID529669Antimicrobial activity against Escherichia coli R4525 expressing gyrA S83L and D87Y and parC S80I and E84G mutant gene by CLSI method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
ISEcp1-mediated transposition of qnrB-like gene in Escherichia coli.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID295347Antibacterial activity against ciprofloxacin resistant methicillin resistant Staphylococcus aureus OC42222007Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10
Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains.
AID57388Minimum inhibitory concentration against Escherichia coli DNA-gyrase in supercoiling assay1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID561397Antibacterial activity against quinolone-susceptible Bordetella pertussis BP58 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Emergence of quinolone-resistant Bordetella pertussis in Japan.
AID405121Antimicrobial activity against Escherichia coli TOP102007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID69602Anti-bacterial activity was tested against Gram-negative EC-1 bacterium1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.
AID544861Antibacterial activity against Streptococcus pneumoniae U2A1413 harboring parC Ser79Tyr mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID556904Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 16 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID206680Antibacterial activity against Staphylococcus pneumoniae KT2524 (PRSP)2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID279823Bactericidal activity in Mycobacterium tuberculosis H37Rv on day 142007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID723107Antibacterial activity against wild type Enterobacter aerogenes ATCC 13048 assessed as growth inhibition after 18 hrs by CLSI broth dilution method2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Search for new tools to combat Gram-negative resistant bacteria among amine derivatives of 5-arylidenehydantoin.
AID209225In vitro antibacterial activity against Streptococcus faecalis 24731990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID133965In vivo potency against acute systemic infection in mouse caused by Pseudomonas aeruginosa UI-18 on oral administration by gavage.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID556889Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 1 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID151528In vitro antibacterial activity against gram negative Pseudomonas aeruginosa UI-18.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID117862Phototoxic skin reaction in depilated female CD-1 mice1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID556861Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 1 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID23542Solubility (in 0.1 N HCl)1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID544832Antibacterial activity against Streptococcus pneumoniae R6 by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID574807Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 761 horboring rpoB S531L/Q510P, katG S315T/R463L, gyrA D94N/S95T, rrs G1484T by CLSI method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID1695898Antibacterial activity against Staphylococcus aureus 209P JC1 incubated for 20 hrs by agar dilution method2019European journal of medicinal chemistry, Apr-15, Volume: 168Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.
AID127505In vitro antibacterial activity against glucose nonfermenter Moraxella bovis P-71011990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID575056Antibacterial activity against Vibrio cholerae O1 mTn-321 harboring Ser to Ile mutation at 83 position in gyrA and parC genes by 2-fold agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Reduced expression of the vca0421 gene of Vibrio cholerae O1 results in innate resistance to ciprofloxacin.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID114069Oral efficacy against Streptococcus pyogenes A65 on Systemic Infections in Mice1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID1557324Toxicity in human assessed as arthralgia effect2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1207773Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits2013Scientific reports, , Volume: 3MICE models: superior to the HERG model in predicting Torsade de Pointes.
AID574806Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 625 horboring rpoB S531L/G566R/I569L, katG S315T/R463L, gyrA A90V/S95T, rrs A1401G by CLSI method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID556878Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 18 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID556653Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 8 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1393818Antitubercular activity against Mycobacterium fortuitum ATCC 6841 by NCCLS method2018European journal of medicinal chemistry, Feb-25, Volume: 146Fluoroquinolone derivatives and their anti-tubercular activities.
AID556901Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 13 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID298864Antibacterial activity against Escherichia coli ATCC 25922 by micro-broth dilution method2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.
AID151052Antibacterial activity was determined against gram negative organism, Pseudomonas aeruginosa UI-181991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID548472Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID1695786Antibacterial activity against Pseudomonas aeruginosa 12 incubated for 20 hrs by agar dilution method2019European journal of medicinal chemistry, Apr-15, Volume: 168Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.
AID51936K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.12002Journal of medicinal chemistry, Aug-29, Volume: 45, Issue:18
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
AID26834Ionisation constant was measured as PKa2; nd = not determined1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria.
AID391986Antibacterial activity against Staphylococcus aureus RN4220 by twofold dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID237457Partition coefficient (logD2.0)2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID434861Antibacterial activity against multidrug-resistant Escherichia coli broth after 24 hrs by broth microdilution method2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Microwave assisted synthesis of new indophenazine 1,3,5-trisubstruted pyrazoline derivatives of benzofuran and their antimicrobial activity.
AID298868Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700699 by micro-broth dilution method2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.
AID755688Binding affinity to human ERG Y652A tetrameric mutant expressed in HEK293 cells assessed as inhibition of tail current measured upon repolarization to -40 mV by patch clamp method2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
AID556688Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 15 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID544851Antibacterial activity against Streptococcus pneumoniae R6 by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID561400Antibacterial activity against quinolone-susceptible Bordetella pertussis BP118 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Emergence of quinolone-resistant Bordetella pertussis in Japan.
AID1557327Phototoxicity in human2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID209769Minimum inhibitory concentration against gram-positive Streptococcus pyogenes C203 (SP1-1)1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria.
AID26624Ionisation constant was measured as PKa1; nd = not determined1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria.
AID556687Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 14 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID445445Permeability at pH 6.5 by PAMPA method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID556699Antimicrobial activity against multidrug resistant Escherichia coli ATCC 35218 harboring pDrive plasmid by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID755690Binding affinity to wild type human ERG expressed in HEK293 cells assessed as inhibition of tail current measured upon repolarization to -40 mV by patch clamp method2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
AID368421Antimicrobial activity against Escherichia coli KAM32 pSTV28 containing chloramphenicol-resistant vector by agar dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID1600107Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1557279Antibacterial activity against Escherichia coli by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID434855Antibacterial activity against multidrug-resistant Streptococcus agalactiae after 20 hrs by cylinder and well method2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Microwave assisted synthesis of new indophenazine 1,3,5-trisubstruted pyrazoline derivatives of benzofuran and their antimicrobial activity.
AID574809Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2474 horboring rpoB H526Y, katG D329A/R463L, gyrA D94G/S95T, rrs A1401G by CLSI method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID164231Antibacterial activity was evaluated against Pseudomonas aeruginosa2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
AID556884Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 24 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID557078Antimicrobial activity against multidrug resistant Escherichia coli DH5[alpha] by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID556862Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 2 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID324745Inhibition of Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as inhibition of pBR322 DNA supercoiling2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID556693Antimicrobial activity against multidrug resistant Enterobacter aerogenes ATCC 15038 harboring pDrive plasmid expressing ampC gene by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID201951In vitro antibacterial activity against gram positive Streptococcus pneumoniae SV-1.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID556903Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 15 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID368424Ratio of MIC for Escherichia coli KAM32 pSTVqepA mutant to MIC for Escherichia coli KAM32 pSTV28 mutant2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID405116Antimicrobial activity against Escherichia coli TOP10 harbouring pVS1 expressing quinolone resistant Vibrio splendidus 12B01 QnrVS1 gene2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID420669Lipophilicity, log D at pH 7.02009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID1600099Antibacterial activity against Staphylococcus epidermidis ATCC 14990 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID755686Binding affinity to human ERG F656A tandem dimeric mutant expressed in HEK293 cells assessed as inhibition of tail current measured upon repolarization to -120 mV by patch clamp method2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
AID279843Ratio of fraction AUC in Mycobacterium tuberculosis infected BALB/c mouse to MIC in Mycobacterium tuberculosis infected BALB/c mouse model at 31 to 50000 mg/kg, po2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID561395Antibacterial activity against quinolone-susceptible Bordetella pertussis BP115 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Emergence of quinolone-resistant Bordetella pertussis in Japan.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID574808Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2301 horboring rpoB S531L, katG R463L/E217G, gyrA D94N/S95T, rrs A1401G by CLSI method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID682292TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, SPLX: 500 uM) in OCTN2-expressing HEK293 cells1999The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
AID260746Inhibition of Bacillus subtilis gyrase activity2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.
AID395097Antitrypanosomal activity against wild type Trypanosoma brucei brucei s427 after 48 hrs by alamar blue assay2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Targeted delivery of compounds to Trypanosoma brucei using the melamine motif.
AID544858Antibacterial activity against Streptococcus pneumoniae H548 clinical isolate harboring gyrA Ser81Phe mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID1297666Bacteriostatic activity against Escherichia coli F-50 measured every 24 hrs for 5 days by broth dilution method2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1557282Antibacterial activity against Bacteroides fragilis by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1600105Antibacterial activity against Escherichia coli ATCC 8739 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID260745Inhibition of Bacillus subtilis topoisomerase4 activity2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.
AID556873Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 13 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID434857Antibacterial activity against multidrug-resistant Streptococcus pneumoniae after 24 hrs by broth microdilution method2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Microwave assisted synthesis of new indophenazine 1,3,5-trisubstruted pyrazoline derivatives of benzofuran and their antimicrobial activity.
AID556678Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 5 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID133971In vivo potency against acute systemic infection in mouse caused by Streptococcus pyogenes C-203 on oral administration by gavage1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID450460Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by twofold serial dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Interaction of drug based binuclear mixed-ligand complexes with DNA.
AID1600104Bactericidal activity against Bacillus subtilis ATCC 6633 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID260744Antibacterial activity against Escherichia coli J532006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.
AID544853Antibacterial activity against Streptococcus pneumoniae R6 Tr6 harboring gyrA Ser81Phe mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID755689Binding affinity to human ERG Y652A tandem dimeric mutant expressed in HEK293 cells assessed as inhibition of tail current measured upon repolarization to -40 mV by patch clamp method2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
AID523002Cytotoxicity against human 5637 cells assessed as mild induction of cell death by LDH release assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
AID556655Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 10 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID556667Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 22 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID391988Antibacterial activity against Staphylococcus aureus RN4220 containing ORI23::qnr-cat promoter mutant by twofold dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID395716Antibacterial activity against Escherichia coli DH10B by twofold dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID436997Inhibition of mouse NIH/3T3 cell proliferation by MTT assay2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID561398Antibacterial activity against quinolone-susceptible Bordetella pertussis BP99 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Emergence of quinolone-resistant Bordetella pertussis in Japan.
AID556656Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 11 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID556696Antimicrobial activity against multidrug resistant Escherichia coli DH5[alpha] harboring pDrive plasmid expressing ampC gene by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID556682Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 9 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID133973In vivo potency against acute systemic infection in mouse caused by Streptococcus pyogenes C-203 on subcutaneous injection1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID405114Antimicrobial activity against Vibrio splendidus 12B01 expressing plasmid-mediated QnrS-like quinolone resistance determinants2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID679030TP_TRANSPORTER: inhibition of DNP-SG uptakee (DNP-SG: 1 uM, SPFX: 3000 uM) in bile canalicular membrane vesicles from EHBR rat1998The Journal of pharmacology and experimental therapeutics, Mar, Volume: 284, Issue:3
Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats.
AID395718Antibacterial activity against Escherichia coli DH10B containing ORI23::qnr-cat promoter mutant by twofold dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID544839Antibacterial activity against Streptococcus pneumoniae H548 clinical isolate harboring gyrA Ser81Phe mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID430965Antibacterial activity against Escherichia coli 1596 containing parC K84 mutant assessed as decrease in MIC by Etest relative to MIC for Escherichia coli 1608 containing gyrA mutant2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.
AID561389Antibacterial activity against quinolone-susceptible Bordetella pertussis BP101 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Emergence of quinolone-resistant Bordetella pertussis in Japan.
AID556902Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 14 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID56393Iinhibitory activity against Escherichia coli DNA topoisomerase IV2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID260737Antibacterial activity against Bacillus subtilis BD542006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1600114Bactericidal activity against methicillin resistant Staphylococcus epidermidis ATCC 13199 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID368422Antimicrobial activity against Escherichia coli KAM32 pSTVqepA containing qepA gene ligated to pSTV28 plasmid by agar dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID544850Antibacterial activity against Streptococcus pneumoniae CIP104485 by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID445446Oral bioavailability in human2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID69490Minimum inhibitory concentration against gram-negative Escherichia coli Vogel (EC-1)1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria.
AID544841Antibacterial activity against Streptococcus pneumoniae U2A1053 harboring parC Ser79Phe mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID530599Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr11 carrying Smqnr gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID556676Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 3 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID209462In vitro antibacterial activity against Streptococcus pyogenes A651990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID557083Antimicrobial activity against multidrug resistant Escherichia coli ATCC 35218 harboring pDrive plasmid by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID198317Antibacterial activity was determined against gram positive organism, Streptococcus pyogenes C2031991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID117692The in vivo potency was determined in female charles river CD-1 mice infected with Streptococcus pyogenes after sc administration1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID548473Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSn mutant gene after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID144438Anti-bacterial activity tested against Mycobacterium smegmatis (ATCG 19420)1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.
AID298858Antibacterial activity against Bacillus subtilis ATCC 6633 by micro-broth dilution method2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.
AID1557323Toxicity in human assessed as gastrointestinal effect2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID133967In vivo potency against acute systemic infection in mouse caused by Streptococcus pneumoniae SV-1 on oral administration by gavage1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID556867Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 7 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID50848In vitro antibacterial activity was tested for Clostridium diff CD1-11995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID556648Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 3 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID434851Antibacterial activity against multidrug-resistant Staphylococcus aureus after 20 hrs by cylinder and well method2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Microwave assisted synthesis of new indophenazine 1,3,5-trisubstruted pyrazoline derivatives of benzofuran and their antimicrobial activity.
AID556875Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 15 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID556646Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 1 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID561393Antibacterial activity against quinolone-susceptible Bordetella pertussis BP112 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Emergence of quinolone-resistant Bordetella pertussis in Japan.
AID203132Minimum inhibitory concentration against gram-positive Staphylococcus aureus H-228 (SA-13)1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria.
AID1600117Antibacterial activity against Serratia marcescens ATCC 12795 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID295343Antibacterial activity against Streptococcus pneumoniae ATCC 496192007Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10
Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains.
AID556868Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 8 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID556697Antimicrobial activity against multidrug resistant Escherichia coli DH5[alpha] harboring pACM204 plasmid by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1557287Antibacterial activity against Enterococcus by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID339999Antimicrobial activity against Pseudomonas aeruginosa2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Structure, antimicrobial activity and DNA-binding properties of the cobalt(II)-sparfloxacin complex.
AID197877Antibacterial activity was determined against gram positive organism, Staphylococcus aureus H2281991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID206882Antibacterial activity against Staphylococcus aureus RN42202004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1600111Antibacterial activity against methicillin resistant Staphylococcus aureus 6347 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID260739Antibacterial activity against Staphylococcus aureus smith2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.
AID561391Antibacterial activity against quinolone-susceptible Bordetella pertussis BP109 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Emergence of quinolone-resistant Bordetella pertussis in Japan.
AID198176Antibacterial activity was determined against gram positive organism, Streptococcus pneumoniae SV-11991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID1695787Antibacterial activity against Escherichia coli NIHJ JC2 incubated for 20 hrs by agar dilution method2019European journal of medicinal chemistry, Apr-15, Volume: 168Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.
AID556700Antimicrobial activity against multidrug resistant Escherichia coli ATCC 35218 harboring pDrive plasmid expressing ampC gene by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID575055Antibacterial activity against Vibrio cholerae O1 CIP0.25-1 harboring Ser to Ile mutation at 83 position in gyrA and parC genes by 2-fold agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Reduced expression of the vca0421 gene of Vibrio cholerae O1 results in innate resistance to ciprofloxacin.
AID556898Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 10 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID556897Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 9 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1600112Bactericidal activity against methicillin resistant Staphylococcus aureus 6347 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID213599Clonogenic cytotoxicity against Chinese hamster V-79 cells1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID209061In vitro antibacterial activity against Streptococcus epidermis 81990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID298872Antibacterial activity against vancomycin-resistant Enterococcus faecium ATCC 700221 by microbroth dilution method2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.
AID557076Antimicrobial activity against multidrug resistant Enterobacter aerogenes ATCC 15038 harboring pACM204 plasmid by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID691688Antibacterial activity against Bartonella henselae infected in african green monkey Vero cells by immunofluorescence staining2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Studies on the antimicrobial properties of N-acylated ciprofloxacins.
AID279837Reduction of Mycobacterium tuberculosis H37Rv in orally dosed BALB/c mouse lung2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID544846Antibacterial activity against Streptococcus pneumoniae R6 Tr10 harboring gyrA Ser81Tyr parC Ser79Tyr mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID298870Antibacterial activity against Enterococcus faecalis ATCC 14506 by microbroth dilution method2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.
AID556660Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 15 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1297671Bactericidal activity against Escherichia coli F-50 incubated for 4 hrs2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones.
AID544866Antibacterial activity against Streptococcus pneumoniae U2A1056 harboring gyrA Ser81Tyr parC Asp83His mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1557286Antibacterial activity against Streptococcus pyogenes by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID164235Anti-bacterial activity tested against Gram-negative PA-7 bacterium1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.
AID160372In vitro antibacterial activity was tested for Propion acnes PA5-11995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
AID544843Antibacterial activity against Streptococcus pneumoniae U2A1693 harboring parC Asp83Asn mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID298862Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by micro-broth dilution method2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.
AID420668Inhibition of human ERG in MCF7 cells2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID1557280Antibacterial activity against Pseudomonas aeruginosa by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID324746Effect on Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as enhancement of supercoiled pBR322 DNA cleavage2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID1600095Antibacterial activity against Staphylococcus aureus ATCC 6538 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID125506The ratio of the number of Mongolian gerbils in which Helicobacter pylori was not detected to that of Mongolian gerbils tested (percent) was represented as clearance rate1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents.
AID298873Antibacterial activity against penicillin-resistant Streptococcus pneumoniae ATCC 700904 by micro-broth dilution method2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.
AID529671Antimicrobial activity against azide-resistant Escherichia coli J53 by CLSI method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
ISEcp1-mediated transposition of qnrB-like gene in Escherichia coli.
AID544852Antibacterial activity against Streptococcus pneumoniae CP1000 by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID544863Antibacterial activity against Streptococcus pneumoniae U2A1411 harboring parC Asp83Gly mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID556686Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 13 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID279821Bactericidal activity in Mycobacterium tuberculosis H37Rv on day 12007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID530594Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr6 carrying Smqnr gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID201409In vitro antibacterial activity against gram positive Staphylococcus aureus UC76.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID557082Antimicrobial activity against multidrug resistant Escherichia coli ATCC 35218 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID561392Antibacterial activity against quinolone-susceptible Bordetella pertussis BP111 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Emergence of quinolone-resistant Bordetella pertussis in Japan.
AID556679Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 6 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID548474Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm mutant gene after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID260743Antibacterial activity against Vancomycin resistant Enterococcus faecium VRE 7008022006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.
AID279822Bactericidal activity in Mycobacterium tuberculosis H37Rv on day 72007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID556684Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 11 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID434856Antibacterial activity against multidrug-resistant Streptococcus pneumoniae after 20 hrs by cylinder and well method2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Microwave assisted synthesis of new indophenazine 1,3,5-trisubstruted pyrazoline derivatives of benzofuran and their antimicrobial activity.
AID556673Antimicrobial activity against multidrug resistant Klebsiella pneumoniae ATCC 11296 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID368418Antimicrobial activity against multidrug-resistant Escherichia coli C316 pHPA containing mutated GyrA gene by agar dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID556661Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 16 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID405115Antimicrobial activity against Vibrio splendidus LGP32 expressing plasmid-mediated QnrS-like quinolone resistance determinants2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID556652Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 7 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID522857Drug level in Escherichia coli UTI89-infected CBA/J mouse urine at 700 ug/kg, po after 2 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
AID544844Antibacterial activity against Streptococcus pneumoniae U2A1411 harboring parC Asp83Gly mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID530597Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr9 carrying Smqnr gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID260742Antibacterial activity against Enterococcus faecium 194342006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.
AID1557281Antibacterial activity against Klebsiella by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID434853Antibacterial activity against multidrug-resistant Salmonella typhi after 20 hrs by cylinder and well method2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Microwave assisted synthesis of new indophenazine 1,3,5-trisubstruted pyrazoline derivatives of benzofuran and their antimicrobial activity.
AID70925In vitro antibacterial activity against Escherichia coli NIHJ JC-21990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID279817Antimicrobial activity against Mycobacterium tuberculosis H37Rv in 7H9 broth2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID530595Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr7 carrying Smqnr gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID279844Ratio of fraction Cmax in Mycobacterium tuberculosis infected BALB/c mouse to MIC in Mycobacterium tuberculosis infected BALB/c mouse model at 31 to 50000 mg/kg, po2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID522867Antibacterial activity against pGEN-GFP carrying uropathogenic Escherichia coli UTI89 isolated from bladder samples of infected CBA/J mouse assessed as decrease in growth of intracellular bacterial community at 12 ug/ml treated 6 hrs postinfection measure2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
AID117691The in vivo potency was determined in female charles river CD-1 mice infected with Streptococcus pyogenes after peroral administration1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID556882Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 22 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID165048In vitro antibacterial activity against Pseudomonas aeruginosa IFO 34451990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID548257Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm, graRm mutant gene after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID544834Antibacterial activity against Streptococcus pneumoniae R6 Tr6 harboring gyrA Ser81Phe mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID450459Antibacterial activity against Serratia marcescens after 24 hrs by twofold serial dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Interaction of drug based binuclear mixed-ligand complexes with DNA.
AID544833Antibacterial activity against Streptococcus pneumoniae CP1000 by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID436988Inhibition of human HeLa cell proliferation2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
AID64389In vitro antibacterial activity against gram negative Enterobacter cloacae MA 2646.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID556887Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 27 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID19421Partition coefficient (logD7.4)1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria.
AID556685Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 12 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID243151Inhibitory concentration against potassium channel HERG2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID556647Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 2 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID556650Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 5 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID144721In vito growth of Mycobacterium tuberculosis BC-437 strain after 6 weeks; - indicates no growth2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Synthesis of galactopyranosyl amino alcohols as a new class of antitubercular and antifungal agents.
AID544856Antibacterial activity against Streptococcus pneumoniae U2A1051 harboring gyrA Ser81Tyr mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID1297672Bactericidal activity against Pseudomonas aeruginosa 9027 incubated for 4 hrs2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones.
AID556657Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 12 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID556900Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 12 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID561390Antibacterial activity against quinolone-susceptible Bordetella pertussis BP106 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Emergence of quinolone-resistant Bordetella pertussis in Japan.
AID544848Antibacterial activity against Streptococcus pneumoniae U2A1060 harboring gyrA Ser81Phe parC Asp83His mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID1164304Inhibition of DNA synthesis in Mycobacterium bovis BCG assessed as inhibition of [3H]adenine incorporation by liquid scintillation counting2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis.
AID408340Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Support vector machines classification of hERG liabilities based on atom types.
AID206857Anti-bacterial activity was tested against Gram-positive SA-13 bacterium1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.
AID556870Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 10 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID530592Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr4 carrying Smqnr gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID556689Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 16 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID544831Antibacterial activity against Streptococcus pneumoniae CIP104485 by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID298865Antibacterial activity against Staphylococcus aureus ATCC 25923 by micro-broth dilution method2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.
AID1557306Protein binding in human at 0.4 g, po2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID64251Antibacterial activity was determined against gram negative organism, Escherichia coli vogel1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID133966In vivo potency against acute systemic infection in mouse caused by Pseudomonas aeruginosa. UI-18. on subcutaneous injection.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID1557285Antibacterial activity against Streptococcus pneumoniae by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID434859Antibacterial activity against multidrug-resistant Pseudomonas aeruginosa after 20 hrs by cylinder and well method2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Microwave assisted synthesis of new indophenazine 1,3,5-trisubstruted pyrazoline derivatives of benzofuran and their antimicrobial activity.
AID561401Antibacterial activity against quinolone-susceptible Bordetella pertussis BP121 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Emergence of quinolone-resistant Bordetella pertussis in Japan.
AID64405The in vivo potency was determined in female charles river CD-1 mice infected with Escherichia coli after sc administration1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID679266TP_TRANSPORTER: transepithelial transport (basal to apical) in Caco-2 cells1998Antimicrobial agents and chemotherapy, Oct, Volume: 42, Issue:10
Secretion of sparfloxacin from the human intestinal Caco-2 cell line is altered by P-glycoprotein inhibitors.
AID279818Antimicrobial activity against Mycobacterium tuberculosis H37Rv infected in mouse J774A.1 macrophages2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID557079Antimicrobial activity against multidrug resistant Escherichia coli DH5[alpha] harboring pDrive plasmid by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID556905Antimicrobial activity against multidrug resistant Enterobacter aerogenes ATCC 15038 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID405118Antimicrobial activity against Escherichia coli TOP10 harbouring pS1 plasmid expressing quinolone resistant QnrS1 gene2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID1164303Inhibition of protein synthesis in Mycobacterium bovis BCG assessed as inhibition of [3H]leucine incorporation by liquid scintillation counting2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis.
AID74723MIC ratio measured as the mean MICs of gram-negative bacteria1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID556876Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 16 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID561394Antibacterial activity against quinolone-susceptible Bordetella pertussis BP113 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Emergence of quinolone-resistant Bordetella pertussis in Japan.
AID1600108Bactericidal activity against Pseudomonas aeruginosa ATCC 9027 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID556877Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 17 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID544838Antibacterial activity against Streptococcus pneumoniae U2A1266 harboring gyrA Ser81Cys mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID561396Antibacterial activity against quinolone-susceptible Bordetella pertussis BP128 by Etest method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Emergence of quinolone-resistant Bordetella pertussis in Japan.
AID1557304AUC in human at 0.4 g, po2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID548254Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID556665Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 20 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID556675Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 2 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID340000Antimicrobial activity against Staphylococcus aureus2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Structure, antimicrobial activity and DNA-binding properties of the cobalt(II)-sparfloxacin complex.
AID680124TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing LLC-PK1 cells2001The Journal of pharmacy and pharmacology, May, Volume: 53, Issue:5
Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein.
AID65042In vitro concentration inhibiting DNA gyrase induced cleavage in Escherichia coli H560.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID556864Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 4 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID556674Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 1 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID295348Antibacterial activity against ciprofloxacin resistant methicillin resistant Staphylococcus aureus OC52732007Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10
Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains.
AID434848Antibacterial activity against multidrug-resistant Streptococcus pyogenes after 20 hrs by cylinder and well method2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Microwave assisted synthesis of new indophenazine 1,3,5-trisubstruted pyrazoline derivatives of benzofuran and their antimicrobial activity.
AID368423Antimicrobial activity against Escherichia coli KAM32 pSTVdeltaqepA containing disrupted qepA gene by agar dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID161281Inhibition of human Potassium channel HERG expressed in mammalian cells2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID279820Antimicrobial activity against Mycobacterium tuberculosis H3Rv on day 72007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID117689The in vivo potency was determined in female charles river CD-1 mice infected with Streptococcus pneumoniae after peroral administration1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID556906Antimicrobial activity against multidrug resistant Enterobacter aerogenes ATCC 15038 harboring pDrive plasmid by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID556891Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 3 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID544865Antibacterial activity against Streptococcus pneumoniae R6 Tr10 harboring gyrA Ser81Tyr parC Ser79Tyr mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID65233In vitro antibacterial activity against gram negative Escherichia coli Vogel.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID205365In vitro antibacterial activity against Serratia marcescence S-91990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID755684Inhibition of human ERG current by patch clamp assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
AID548471Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 48 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID523001Cytotoxicity against human 5637 cells assessed as mild induction of cell death by trypan blue exclusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
AID755685Binding affinity to human ERG F656A tetrameric mutant expressed in HEK293 cells assessed as inhibition of tail current measured upon repolarization to -120 mV by patch clamp method2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
AID1600118Bactericidal activity against Serratia marcescens ATCC 12795 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID530591Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr3 carrying Smqnr gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID133962In vivo potency against acute systemic infection in mouse caused by Escherichia coli vogel on subcutaneous injection.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID556881Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 21 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID405120Antimicrobial activity against Escherichia coli TOP10 harbouring p0 plasmid expressing pCR-BluntII-TOPO2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID70926In vitro antibacterial activity against Escherichia coli P-51011990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID556871Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 11 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID202109In vitro antibacterial activity against gram positive Streptococcus pyogenes C-203.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID268191Antimicrobial activity against Staphylococcus aureus2006Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14
Crystal structure, spectroscopic, and biological study of the copper(II) complex with third-generation quinolone antibiotic sparfloxacin.
AID144715In vito growth of Mycobacterium tuberculosis BC-243 strain after 6 weeks; - indicates no growth2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Synthesis of galactopyranosyl amino alcohols as a new class of antitubercular and antifungal agents.
AID339998Antimicrobial activity against Escherichia coli2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Structure, antimicrobial activity and DNA-binding properties of the cobalt(II)-sparfloxacin complex.
AID68191In vitro antibacterial activity against Enterobacter cloacae 9631990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID152317In vitro antibacterial activity against gram negative Providencia rettgeri M-1771.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID556677Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 4 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID15883Calculated partition coefficient (clogP)1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID544868Antibacterial activity against Streptococcus pneumoniae U2A1414 harboring gyrA Glu85Lys parC Ser79Phe mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID556654Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 9 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID544835Antibacterial activity against Streptococcus pneumoniae U2A1686 harboring gyrA Glu85Lys mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID1600098Bactericidal activity against methicillin resistant Staphylococcus aureus N315 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1659029Photoirradiation factor, ratio of IC50 for BALB/c mouse 3T3 cells under dark condition to IC50 for BALB/c mouse 3T3 cells under 5 J/cm2 sunlight irradiation by neutral red uptake assay2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria.
AID206283In vitro antibacterial activity against Staphylococcus aureus 209P JC-11990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID87939In vitro minimum inhibitory concentration against growth of Helicobacter pylori ATCC 43504.1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents.
AID1600101Antibacterial activity against Enterococcus hirae ATCC 1052 cultured in BHI medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID556883Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 23 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID405119Antimicrobial activity against Escherichia coli TOP10 harbouring pS2 plasmid expressing quinolone resistant QnrS2 gene2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID556885Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 25 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID298867Antibacterial activity against Staphylococcus aureus ATCC 33592 by micro-broth dilution method2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.
AID574810Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2911 horboring rpoB D516V, katG S315T/R463L, gyrA D94G/S95T/R128S/Y129C, rrs A1401G by CLSI method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID523004Antibacterial activity against uropathogenic Escherichia coli UTI89 assessed as degradation of preexisting biofilm after 24 hrs by microscopy2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
AID63898Antibacterial activity was determined against gram negative organism, Enterobacter cloacae MA26461991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID133960In vivo potency against acute systemic infection in mouse caused by Escherichia coli Vogel on oral administration by gavage.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID1600110Bactericidal activity against Proteus vulgaris NCTC 4635 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID23544Solubility (at pH 4)1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID544840Antibacterial activity against Streptococcus pneumoniae R6 Tr1 harboring parC Ser79Tyr mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID575057Antibacterial activity against Escherichia coli JM109 harboring plasmid ptac852010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Reduced expression of the vca0421 gene of Vibrio cholerae O1 results in innate resistance to ciprofloxacin.
AID295339Inhibition of bacterial DNA gyrase2007Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10
Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains.
AID575058Antibacterial activity against Escherichia coli JM109 harboring plasmid ptac85-vca04212010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Reduced expression of the vca0421 gene of Vibrio cholerae O1 results in innate resistance to ciprofloxacin.
AID295344Antibacterial activity against quinolone susceptible methicillin resistant Staphylococcus aureus OC28782007Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10
Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains.
AID522865Antibacterial activity against uropathogenic Escherichia coli UTI89 infected in CBA/J mouse assessed as decrease in bacterial invasion into layers of urothelium at 700 ug/kg, po administered on day 3 postinfection daily for 3 days measured on day 9 post-i2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
AID529670Antimicrobial activity against Escherichia coli J53 transconjugate by CLSI method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
ISEcp1-mediated transposition of qnrB-like gene in Escherichia coli.
AID405117Antimicrobial activity against Escherichia coli TOP10 harbouring pVS2 expressing quinolone resistant Vibrio splendidus LGP32 QnrVS2 gene2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID1600116Bactericidal activity against Streptococcus pneumoniae cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID53448Iinhibitory activity against Staphylococcus aureus DNA gyrase2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID523003Antibacterial activity against uropathogenic Escherichia coli UTI89 assessed as inhibition of biofilm formation after 24 hrs by microtiterplate-based assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID279829AUC(0-infinity) in BALB/c mouse at 5 to 1000 mg/kg, po2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID544842Antibacterial activity against Streptococcus pneumoniae U2A1413 harboring parC Ser79Tyr mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID23549Solubility (at pH 7.4)1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID1557328Cardiotoxicity in human QTc prolongation2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID556880Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 20 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID556894Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 6 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1557305Half life in human at 0.4 g, po2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID556695Antimicrobial activity against multidrug resistant Escherichia coli DH5[alpha] harboring pDrive plasmid by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID206878Antibacterial activity against Staphylococcus aureus KMP9 (MRSA)2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID1600103Antibacterial activity against Bacillus subtilis ATCC 6633 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID544855Antibacterial activity against Streptococcus pneumoniae U2A1050 harboring gyrA Ser81Phe mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID392220Antibacterial activity against Lactococcus lactis IL-1419 containing ORI23 promoter by twofold dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID133969In vivo potency against acute systemic infection in mouse caused by Streptococcus pneumoniae SV-1 on subcutaneous injection1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID530590Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr2 carrying Smqnr gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID544847Antibacterial activity against Streptococcus pneumoniae U2A1056 harboring gyrA Ser81Tyr parC Asp83His mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID557080Antimicrobial activity against multidrug resistant Escherichia coli DH5[alpha] harboring pDrive plasmid expressing ampC gene by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID557084Antimicrobial activity against multidrug resistant Escherichia coli ATCC 35218 harboring pDrive plasmid expressing ampC gene by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID16467Calculated partition coefficient (clogP)1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria.
AID1600100Bactericidal activity against Staphylococcus epidermidis ATCC 14990 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID556872Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 12 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID298871Antibacterial activity against vancomycin-resistant Enterococcus faecalis ATCC 700802 by micro-broth dilution method2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID56395Iinhibitory activity against human DNA topoisomerase II2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID556896Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 8 by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID283088Antibacterial activity against Staphylococcus aureus SA1199B overexpressing NorA at 5 ug by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID544854Antibacterial activity against Streptococcus pneumoniae U2A1686 harboring gyrA Glu85Lys mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID243188Inhibition of human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel) in open state2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
A two-state homology model of the hERG K+ channel: application to ligand binding.
AID279819Fraction unbound ligand in mouse plasma at 0.01 to 50 mg/litre2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID481442Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID434860Antibacterial activity against multidrug-resistant Escherichia coli after 20 hrs by cylinder and well method2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Microwave assisted synthesis of new indophenazine 1,3,5-trisubstruted pyrazoline derivatives of benzofuran and their antimicrobial activity.
AID67922Antibacterial activity evaluated against Enterococcus faecalis2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
AID530596Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr8 carrying Smqnr gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID135327BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID1297665Bacteriostatic activity against Pseudomonas aeruginosa 9027 measured every 24 hrs for 5 days by broth dilution method2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones.
AID544849Antibacterial activity against Streptococcus pneumoniae U2A1414 harboring gyrA Glu85Lys parC Ser79Phe mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID557077Antimicrobial activity against multidrug resistant Enterobacter aerogenes ATCC 15038 harboring pDrive plasmid expressing ampC gene by broth dilution method in presence of 26.3 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID556666Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 21 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID65397In vitro antibacterial activity against gram positive Enterococcus faecalis MGH-2.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID198021Antibacterial activity was determined against gram positive organism, Streptococcus faecalis MGH-21991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID279832Half life in BALB/c mouse at 5 to 1000 mg/kg, po2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID368420Antimicrobial activity against Escherichia coli KAM32 pHPA containing mutated GyrA gene by agar dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID295340Inhibition of bacterial DNA topoisomerase 42007Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10
Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains.
AID556698Antimicrobial activity against multidrug resistant Escherichia coli ATCC 35218 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID114067Oral efficacy against Pseudomonas aeruginosa 12 on Systemic Infections in Mice1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID151374Antibacterial activity was determined against gram negative organism, Providencia rettgeri. M17711991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
AID544845Antibacterial activity against Streptococcus pneumoniae U2A1681 harboring parC Ser79Tyr Asp83Ala mutant gene by agar disk diffusion method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID298859Antibacterial activity against Staphylococcus epidermidis ATCC 12228 by micro-broth dilution method2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.
AID530593Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr5 carrying Smqnr gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID556651Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 6 by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID548253Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 24 hrs by Etest2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID406844Antibacterial activity against Escherichia coli TOP10 by E-test2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant.
AID523006Antibacterial activity against uropathogenic Escherichia coli UTI89 infected in CBA/J mouse assessed as decrease in bacterial load in bladder at 700 ug/kg, po administered on day 3 postinfection daily for 3 days measured on day 9 post-inoculation2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID450458Antibacterial activity against Bacillus subtilis after 24 hrs by twofold serial dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Interaction of drug based binuclear mixed-ligand complexes with DNA.
AID1297667Bacteriostatic activity against Bacillus cereus 8035 measured every 24 hrs for 5 days by broth dilution method2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones.
AID434849Antibacterial activity against multidrug-resistant Streptococcus pyogenes after 24 hrs by broth microdilution method2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Microwave assisted synthesis of new indophenazine 1,3,5-trisubstruted pyrazoline derivatives of benzofuran and their antimicrobial activity.
AID391987Antibacterial activity against Staphylococcus aureus RN4220 containing ORI23 promoter by twofold dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID530588Antimicrobial activity against Escherichia coli TOP10 by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID556692Antimicrobial activity against multidrug resistant Enterobacter aerogenes ATCC 15038 harboring pACM204 plasmid by broth dilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID144723In vito growth of Mycobacterium tuberculosis VA-101 strain after 6 weeks; - indicates 1-20 colonies2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Synthesis of galactopyranosyl amino alcohols as a new class of antitubercular and antifungal agents.
AID523009Antibacterial activity against uropathogenic Escherichia coli UTI89 isolated from urine samples of infected CBA/J mouse after 24 hrs by disk diffusion assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID298869Antibacterial activity against linezolid-resistant Staphylococcus aureus NRS 119 by microbroth dilution method2007Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7
Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.
AID1600109Antibacterial activity against Proteus vulgaris NCTC 4635 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (650)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (0.31)18.7374
1990's364 (56.00)18.2507
2000's184 (28.31)29.6817
2010's81 (12.46)24.3611
2020's19 (2.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.52 (24.57)
Research Supply Index6.64 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index84.74 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (53.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials69 (9.94%)5.53%
Reviews31 (4.47%)6.00%
Case Studies27 (3.89%)4.05%
Observational0 (0.00%)0.25%
Other567 (81.70%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]